Poster Session 1 – Wednesday, December 8, 2021: 7:00 am – 8:30 am CT
   
  Axillary Staging and Sentinel Nodes
P1-01-01 Prospective ultrasonographic surveillance study for incidence and recovery period of COVID-19 vaccination-related axillary lymphadenopathy
Kida K, Tsunoda H, Kasahara R, Tsutsumi C, Numata A, Takehara Y, Yoshida A, Takei J, Hayashi N, Kobayashi D, Yamauchi H. St. Luke's International Hospital, Tokyo, Japan.
P1-01-02 Pathologic nodal status is a predictor for metastatic disease in lymph nodes identified by axillary reverse mapping
Saengphongchawan R, Manasnayakorn S. King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
P1-01-03 Feasibility and diagnostic performance of ultrasound assisted carbon nanoparticle suspension versus dual-tracer-guided sentinel lymph node mapping in patients with early breast cancer: A prospective, randomized controlled, phase III clinical trial
Cheng M, Zhang L, Chen Y, Zhuang X, Yang C, Ji F, Gao H, Yang M, Zhu T, Li J. Department of Breast Cancer, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
P1-01-04 RUFY3 as a predictive intratumor biomarker for lymph node metastasis in older women with invasive breast cancer
Angarita FA, Oshi M, Yamada A, Yan L, Matsuyama R, Edge SB, Endo I, Takabe K. Roswell Park Comprehensive Cancer Center, Buffalo, NY; Yokohama City University Graduate School of Medicine, Kanagawa, Japan; Yokohama City University Graduate School of Medicine, Yokohama, Japan.
P1-01-05 Influence of age and tumor size on lymph node positivity in breast cancer: A retrospective population study on the US SEER database
Pinchuk M, Laenen A, Hatse S, Punie K, Neven P, Nevelsteen I, Wildiers H. KU Leuven, Leuven, Belgium.
P1-01-06 Predictor of sentinel node positivity in screen-detected invasive breast cancer
Bichoo RA, Elahi MB, Dumitru D, Ihsan NB, Khalifa E, Sarker M, Mahapatra TK, Wooler BP, Kneeshaw P, Grover K. Hull University Teaching Hospital NHS Trust, Cottingham, United Kingdom.
P1-01-07 Factors predicting a lower likelihood of residual nodal disease in clinically-node positive patients undergoing sentinel node surgery after neoadjuvant chemotherapy for breast cancer
Cabioglu N, Karanlık H, Igci A, Muslumanoglu M, Tukenmez M, Emiroglu S, Ozkurt E, Onder S, Saip P, Eralp Y, Aydiner A, Yavuz E, Ozmen V. Istanbul University, Istanbul Faculty of Medicine, Department of Surgery, Istanbul, Turkey; Istanbul University, Institute of Oncology, Surgical Oncology Division, Istanbul, Turkey; American Hospital, Department of Surgery, Istanbul, Turkey; Ozel Basari Hospital, Department of Surgery, Istanbul, Turkey; Istanbul University, Istanbul Faculty of Medicine, Department of Pathology, Istanbul, Turkey; Istanbul University, Institute of Oncology, Department of Medical Oncology, Istanbul, Turkey; Acibadem Maslak Hospital, Acibadem Health Group, Istanbul, Turkey; Tuzlali Pathology Laboratory, Istanbul, Turkey.
P1-01-08 Axillary surgery after neoadjuvant chemotherapy in breast cancer - Survey among Argentinian breast surgeons
Azar ME, Mansilla F. MD, Cavallero J, Sturla O, Ursino H, Berman G, Ipiña M, Aguilar A, Caceres V, Gonzalez E. Instituto Oncologico Angel H. Roffo, Buenos Aires, Argentina.
P1-01-09 Prediction of node negative breast cancer and high disease burden through image analysis software on mammographic images and clinicopathological data
Rejmer C, Dihge L, Bendahl P-O, Förnvik D, Dustler M, Rydén L. Department of Clinical Sciences, Division of Surgery, Lund University, Lund, Sweden; Department of Clinical Sciences, Division of Surgery, Lund University, and Department of Plastic and Reconstructive Surgery, Skåne University Hospital, Lund and Malmö, Sweden; Department of Clinical Sciences, Division of Oncology, Lund University, Lund, Sweden; Diagnostic Radiology, Department of Translational Medicine, Faculty of Medicine, Lund University, and Medical Radiation Physics, Department of Translational Medicine, Skåne University Hospital, Lund University, Lund and Malmö, Sweden; Diagnostic Radiology, Department of Translational Medicine, Faculty of Medicine, Lund University, Lund, Sweden; Department of Clinical Sciences, Division of Surgery, Lund University, and Department of Surgery, Skåne University Hospital, and Aarhus University, Lund and Aarhus, Sweden.
P1-01-10 A phase 3, multicenter, self-controlled, non-inferiority trial comparing mitoxantrone hydrochloride injection for tracing versus technetium-99m in the detection of axillary sentinel nodes in patients with early-stage breast cancer
Yang B, Jiao D, Chen J, Wang C, Jin L, Zhao W, Gao X, Wang H, Li J, Zhao H, Wu D, Fan Z, Wang S, Liu Z, Wang Y, Wu J. Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China, Shanghai, China; Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China; Shandong Cancer Hospital, Jinan, China; Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China; The Affiliated Hospital of Qingdao University, Qingdao, China; The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China, Qingdao, China; Second Affiliated Hospital of Dalian Medical University, Dalian, China; The First Bethune Hospital of Jilin University, Changchun, China, Changchun, China; The First Bethune Hospital of Jilin University, Changchun, China; Shenyang Pharmaceutical University, Shenyang, China, Shanghai, China; Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China, Zhengzhou, China; Shandong Cancer Hospital, Jinan, China, Jinan, China.
P1-01-11 Axillary extensive burden evaluation by ultrasound in preoperative nodal staging in breast cancer patients
Defoort C, Chemaly J, Ceugnart L, Chauvet M-P. Centre Oscar Lambret, Lille, France.
P1-01-12 Withdrawn
P1-01-13 A prospective self-controlled study of indocyanine green instead of radioisotope for axillary sentinel lymph nodes in breast cancer
Jin Y, Yuan L, Jiang J, Qi X. Army Medical University, Chongqing, China.
P1-01-14 Axillary assessment by Systemic Axillary Sonography (SAS) for axillary disease treated with neoadjuvant chemotherapy
Melnikau S, Layton C, Ozmen T, Allen M, Avisar E. University of Miami Miller School of Medicine/Jackson Memorial Hospital, Miami, FL; Florida Atlantic University, Charles E. Schmidt College of Medicine, Miami, FL; University of Miami Miller School of Medicine, Miami, FL.
P1-01-15 Clinical relevance of TRIM37 gene expression in breast cancer
Tsuchida J, Wu R, Endo M, Moro K, Toshikawa C, Koyama Y, Ichikawa H, Hanyu T, Takabe Y, Takizawa K, Shimada Y, Kobayashi T, Ishikawa T, Sakata J, Wakai T, Takabe K. Niigata University, Niigata, Japan; Roswell Park Comprehensive Cancer Center, Buffalo, NY.
P1-01-16 Perspectives on axillary management after primary systemic treatment: An international EUBREAST survey
Gasparri ML, De Boniface J, Gentilini OD, Kaidar-Person O, Poortmans P, Kuehn T. University of the Italian Switzerland, Ente Ospedaliero Cantonale of Lugano, Lugano, Switzerland; Karolinska Institutet, Stockholm, Sweden; San Raffaele University Hospital, Milan, Italy; Oncology Institute, Sheba Hospital Tel Hashomer, Ramat Gan, Israel; Iridium Kankernetwerk, Wilrijk-Antwerp, Belgium; Klinikum Esslingen, Esslingen, Germany.
P1-01-17 Machine learning-based DNA methylation classifiers to predict pathologic nodal stage in breast cancer patients with clinically node positive disease
DiNome ML, Ensenyat-Mendez M, Orozco JIJ, Rünger D, Baker JL, Weidhaas JB, Marzese DM. UCLA, Los Angeles, CA; Institut d'Investigació Sanitària Illes Balears (IdISBa), Palma, Spain; Saint John's Cancer Institute, Santa Monica, CA.
   
  Detection/Diagnosis - Pathology: Diagnostic Pathology
P1-02-01 Deep learning identifies morphological changes in whole slide images of treatment-resistant TNBC
Foroughi Pour A, Wu T-C, Martinek J, Kumar S, Anzeneder T, Torkler S, Sommermeyer F, Palucka K, Chuang J. The Jackson Laboratory, Farmington, CT; Stiftung PATH - Patients' Tumor Bank of Hope, Munich, Germany.
P1-02-02 Examination of low Her2 expression in breast cancer
Fernandez AI, Liu M, Bellizzi A, Brock J, Fadare O, Hanley K, Harigopal M, Jorns JM, Kuba MG, Ly A, Podoll M, Rabe K, Sanders MA, Singh K, Snir OL, Soong R, Wei S, Wen H, Wong S, Yoon E, Pusztai L, Reisenbichler E, Rimm DL. Yale University, New Haven, CT; University of Iowa, Iowa City, IA; Brigham and Women’s Hospital, Boston, MA; University of California San Diego, San Diego, CA; Emory University, Atlanta, GA; Medical College of Wisconsin, Milwaukee, WI; Memorial Sloan Kettering Cancer Center, New York, NY; Massachusetts General Hospital, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; University of Minnesota, Minneapolis, MN; Norton Healthcare, Louisville, KY; Brown University, Providence, RI; Oregon Health & Science University, Portland, OR; University of Pittsburgh Medical Center, Pittsburgh, PA; University of Alabama at Birmingham, Birmingham, AL; MD Anderson Cancer Center, Houston, TX.
P1-02-03 Tumor-infiltrating lymphocytes but not HER2 copy number or ratio show prognostic value in trastuzumab-treated HER2-positive breast cancer
Robertson S, Rönnlund C, Fredriksson I, Foukakis T, Hartman J. Department of Oncology-Pathology, Karolinska Institutet and Dept of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institutet and Dept of Breast-, Endocrine Tumors and Sarcoma, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institutet and Breast Center, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institutet and Dept of Clinical Pathology and Cancer Diagnostics, and MedtechLabs Bioclinicum, Karolinska University Hospital, Stockholm, Sweden.
P1-02-04 Modified Miller-Payne score as a pragmatic and efficient alternative to Residual Cancer Burden
Hall PS, Ironside A, Tramonti G, Cavanagh A, Quiohilag K, Oikonomidou O. University of Edinburgh, Edinburgh, United Kingdom; NHS Lothian, Edinburgh, United Kingdom.
P1-02-05 A genome-wide functional genomics screen reveals unique co-driver mutations of mutant TP53 promoting cellular heterogeneity during breast cancer progression
Grief D, Pal A, Gonzalez-Malerva L, Eaton S, Xu C, Christensen G, Blain J, Mellor N, Steel J, Gupta C, Ellen Streitwieser, Singharoy A, Park J, LaBaer J. The Biodesign Institute - Arizona State University, Tempe, AZ.
P1-02-06 Prediction of Prosigna® breast cancer intrinsic subtype by immunohistochemical ER, PR and Ki67 expression
Heber U, Tendl-Schulz K, Heber S, Danzinger S, Bartsch R, Singer CF, Fitzal F, Exner R, Gnant MF, Müllauer L, Bago-Horvath Z. Department of Pathology, Medical University of Vienna, Wien, Austria; Center for Physiology and Pharmacology, Medical University of Vienna, Wien, Austria; Department of Obstetrics and Gynecology, Medical University of Vienna, Wien, Austria; Department of Medicine 1, Clinical Division of Oncology, Medical University of Vienna, Wien, Austria; Department of Surgery, Medical University of Vienna, Wien, Austria; Comprehensive Cancer Center, Medical University of Vienna, Wien, Austria.
P1-02-07 Accuracy and predictive value of resection margin assessment by intraoperative frozen section after neoadjuvant therapy: An analysis of the ABCSG 24 and 34 trials
Rokitte K, Tendl-Schulz K, Heber U, Wimmer K, Bartsch R, Kacerovsky-Strobl S, Pfeiler G, Steger GG, Singer CF, Hlauschek D, Gnant M, Fitzal F, Bago-Horvath Z. Department of Pathology, Medical University of Vienna, Wien, Austria; Department of Surgery, Medical University of Vienna, Wien, Austria; Department of Medicine 1, Clinical Division of Oncology, Medical University of Vienna, Wien, Austria; Department of Gynecology and Obstetrics, Medical University of Vienna, Wien, Austria; Austrian Breast and Colorectal Cancer Study Group, Wien, Austria; Comprehensive Cancer Center, Medical University of Vienna, Wien, Austria.
P1-02-08 Comparison of clinical features and outcomes for pleomorphic invasive lobular carcinoma vs. non-pleomorphic invasive lobular carcinoma
Wright MD, Dempster MS, ElSherif A, Cocco D, Valente SA, Li H, Kruse ML. Cleveland Clinic, Cleveland, OH.
P1-02-09 Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer (ILC)
De Schepper M, Vincent-Salomon A, Christgen M, Van Baelen K, Tsuda H, Kurozumi S, Brito MJ, Cserni G, Schnitt S, Larsimont D, Kulka J, Fernandez PL, Rodriguez P, Aula A, Mendelez C, Van Bockstal M, Kovacs A, Varga Z, Wesseling J, Bhargava R, Boström P, Franchet C, Zambuko B, Matute G, Berghian A, van Diest P, Oesterreich S, Derksen PWB, Floris G, Desmedt C. Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium; Diagnostic and Theranostic Medicine Division, Institut Curie, PSL Research University, Paris, France; Institute of Pathology, Hannover Medical School, Hannover, Germany; Department of Pathology, National Defense Medical College Hospital, Tokorozawa, Saitama, Japan; Department of Breast Surgery, International University of Health and Welfare, Chiba, Japan, Japan; Breast Unit, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal; Department of Pathology, Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary; Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA; Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium; 2nd Department of Pathology, Semmelweis University, Budapest, Pest, Hungary; Hospital German Trias i Pujol, Badalona, Spain; University Hospital Doctor Josep Trueta, Girona, Spain; Department of Pathology, Cliniques Universitaires Saint-Luc Bruxelles, Woluwé-Saint-Lambert, Belgium; Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden; Institut für Pathologie und Molekularpathologie, Universitätsspital Zürich, Zürich, Switzerland; Divisions of Molecular Pathology and Diagnostic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands; Women's Cancer Research Center, UPMC Hillman Cancer Center, Magee-Womens Research Institute, Pittsburgh, PA; Department of Pathology, Turku University Hospital and University of Turku, Turku, Finland; Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France; Department of Pathology, Sir Ketumile Masire Teaching Hospital, University of Botswana, Gaborone, Botswana; Clínica Universitaria Bolivariana, Universidad Pontificia Bolivariana, Medellín, Colombia; Département de biopathologie, Centre Henri Becquerel, Rouen, France; Department of Pathology, University Medical Center Utrecht, Utrecht, Netherlands; Department of Pathology, University Hospitals Leuven, UZ Leuven, Leuven, Belgium.
P1-02-10 Breast tumor measurement after neoadjuvant chemotherapy using the 8<sup>th</sup> edition of the American Joint Committee on cancer staging system: Impact on estimates of tumor size and discrepancies with residual cancer burden class
Harter D, O'Connor SM, Hertel JD, Calhoun BC. University of North Carolina, Chapel Hill, NC.
P1-02-11 Somatic alterations and PD-L1 positivity in advanced breast cancer
Finkelman BS, Cristofanilli M, Blanco, Jr LZ, Behdad A, Platanias LC, Gradishar WJ, Siziopikou KP. Northwestern University Feinberg School of Medicine, Chicago, IL.
P1-02-12 Genomic testing on breast cancer core biopsy material is feasible and provides useful treatment information
Bomeisl P, Montero A, Gilmore H. University Hospitals of Cleveland, Cleveland, OH.
P1-02-13 Tumour infiltrating lymphocytes (TILs) and immune composition in breast cancer patients from Kenya: Spatial distributions and associations with risk factors and tumour characteristics
Sayed S, Yang XR, Govender D, Breast Health Study group. Aga Khan University Hospital, Nairobi and University of Cape Town, Nairobi, Kenya and Cape Town South Africa, Kenya; National Cancer Institute(NCI), Bethesda, MD; University of Cape Town, Cape Town, South Africa.
P1-02-14 A comparative analysis of clinical and pathologic characteristics of patients with HER2 positive breast cancer treated with neoadjuvant versus adjuvant anti-HER2 therapy: Analysis of 397 cases
Sarode V, Rood T, Liu Y, Fang Y, Sahoo S, Peng Y, Hwang H, Leitch M, Haley B. UT Southwestern Medical Center, Dallas, TX.
P1-02-15 Predicting molecular subtypes of breast cancer using
Huang C-C, Phan NN, Tseng L-M. Taipei Veterans General Hospital, Taipei, Taiwan; National Taiwan University, Taipei, Taiwan.
P1-02-16 Prediction of breast ductal carcinoma in situ recurrence using histomics analysis of stromal collagen from second-harmonic generation and hematoxylin and eosin stain-based images
Upadhaya T, Hayward M-K, Kim M-O, Balassanian R, Weaver V, Morin O, Park C. University of California San Francisco, San Francisco, CA.
P1-02-17 Artificial intelligence-based whole slide scoring of nuclear breast cancer IHC markers Ki67, ER, and PR matches performance of manual clinical scoring
Kapadia M, Khojasteh M, Kouzova M, Jones C, Xu X-M, Olson MT, Gladden S, Sapanara N, Singh S, Chen CC, Isaac Bai1, Ranger-Moore J, Inge LJ, Kurkure U, Bhattacharya I, Zhao M, Zuiderveld K, Chintakindi C, Lopez B, Guetter C. Roche Tissue Diagnostics, Tucson, AZ; Roche Tissue Diagnostics, Santa Clara, CA.
   
  Detection/Diagnosis - Pathology: Biopsy Techniques
P1-03-01 Heterogeneity between core needle biopsy and primary tumor tissue in early breast cancer patients: Comparison of intrinsic subtypes after different treatment regimes
Weydandt L, Kreklau A, Nel I, Horn L-C, Aktas B. University Hospital of Leipzig, Leipzig, Germany.
P1-03-02 Clip placement after ultrasound guided biopsy in the setting of neoadjuvant chemotherapy
Yong-Hing CJ, Ito C, Corke L, Simmons C, Abrahams B. BC Cancer, Vancouver, BC, Canada.
   
  Tumor Cell and Molecular Biology: Immunology and Preclinical Immunotherapy
P1-04-01 Digital spatial profiling of immune-related proteins in luminal androgen receptor (LAR) vs non-LAR triple-negative breast cancer (TNBC)
Leon-Ferre RA, Carter JM, Zahrieh DM, Hillman DW, Chumsri S, Ma Y, Kachergus JM, Wang X, Boughey JC, Liu MC, Ingle JN, Kalari KR, Villasboas Bisneto JC, Couch FJ, Thompson EA, Goetz MP. Mayo Clinic, Rochester, MN.
P1-04-02 Immune milieu associated with PD-L1 status in TNBC is dependent on time of biomarker assessment and treatment received: a secondary analysis of the NeoTRIPaPDL1 trial
Callari M, Huang C-S, Egle D, Bermejo B, Zamagni C, Dugo M, Thill M, Anton A, Barreca M, Russo S, Ciruelos EM, Greil R, Zambelli S, Gyorffy B, Smart C, Biasi O, Valagussa P, Viale G, Gianni L, Bianchini G. Fondazione Michelangelo, Milan, Italy; Breast Center, National Taiwan University Hospital, Taiwan, Taiwan; Medical University of Innsbruck, Innsbruck, Austria; Hospital Clinico Universitario de Valencia, Valencia, Spain; IRCCS Azienda ospedaliero Universitaria di Bologna, Bologna, Italy; IRCCS Ospedale San Raffaele, Milan, Italy; Agaplesion Markus Krankenhaus, Frankfurt am Main, Germany; University Hospital Miguel Servet, Zaragoza, Spain;Fondazione MichelangeloAzienda Sanitaria Universitaria Friuli Centrale, Udine, Italy; Hospital Universitario 12 de Octubre, Madrid, Spain; IIIrd Medical Department, Paracelsus Medical University Salzburg; Salzburg Cancer Research Institute-CCCIT; and Cancer Cluster Salzburg, Salzburg, Austria; Semmelweis University, Budapest, Hungary; Istituto Europeo di Oncologia, Milan, Italy.
P1-04-03 Host myeloid response to tumor and immunotherapy is associated with heterogeneity in outcomes to anti-PDL1
Hanna A, Sun X, Gonzalez-Ericsson PI, Sanchez VM, Sanders ME, Balko JM. Vanderbilt University Medical Center, Nashville, TN.
P1-04-04 Dna barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and in response to immunotherapy
Baldwin LA, Bartonicek N, Yang J, Wu SZ, Deng N, Roden D, Chan C-L, Al-Eryani G, Zanker DJ, Parker BS, Swarbrick A, Junankar S. Garvan Institute of Medical Research, Sydney, Australia; Sir Peter MacCallum Department of Oncology, Melbourne, Australia.
P1-04-05 Multiplexed immunofluorescence staining of intra-tumoral immune cell populations and associations with immunohistochemical, clinical, and pathologic variables in breast cancer
O'Meara TA, Keenan TE, Waks AG, Felt KD, Sharma B, Rodig S, Hughes M, Lin NU, Agudo J, Guerriero JL, McAllister SS, Mittendorf E, Tolaney S. Brigham and Women's Hospital, Department of Medicine, Boston, MA; Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Department of Pathology, Boston, MA; Brigham and Women's Hospital, Department of Surgery, Boston, MA.
P1-04-06 Semaphorin7a expression in breast cancers promotes susceptibility to immune checkpoint blockade
Elder A, Stoller A, Lyons T. University of Colorado, Aurora, CO.
P1-04-07 Xiap expression is associated with infiltration of cd163+ tumor-associated macrophages in the tumor micro-environment of inflammatory breast cancer
Van Berckelaer C, Van Laere S, Gerardts J, Dirix L, Morse M, Kockx M, Bertucci F, Van Dam P, Devi GR. Multidisciplinary Breast Clinic, Unit Gynaecologic Oncology; Antwerp University Hospital (UZA) (Belgium); Molecular Imaging, Pathology, Radiotherapy, Oncology (MIPRO); Faculty of Medicine and Health Sciences; University of Antwerp, Antwerp, Belgium; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, Belgium; Department of Pathology, East Carolina University, Greenville, NC; Translational Cancer Research Unit, GZA Hospitals & CORE, University of Antwerp, Antwerpen, Belgium; Department of Medicine, Duke University, Durham, NC; CellCarta, Antwerp, Belgium; Predictive Oncology team, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, CNRS, Aix-Marseille Université, Institut Paoli-Calmettes, Marseille, France; Department of Surgery, Duke University, Durham, NC.
P1-04-08 Exosomes from primary breast adipocytes induce immune exhaustion in triple negative breast cancer
Jafari N, Kolla M, Pompa I, Meshulam T, Batista Junior M, Denis GV. Boston University, Boston, MA.
P1-04-09 Essential role for MUC1-C in chronic activation of cytosolic nucleotide sensing and the type I interferon pathway in triple-negative breast cancer
Yamashita N, Fushimi A, Morimoto Y, Bhattacharya A, Long M, Liu S, Kufe D. Dana-Farber Cancer Institute, Boston, MA; Roswell Park Comprehensive Cancer Center, Buffalo, NY.
P1-04-10 Breast cancer survivors exhibit an accumulation of CD4+ central memory T cells, a fall in CD8+ naïve T cells and higher activation of CD4+/CD8+ memory T cells and higher activation of CD4+/CD8+ memory T cells in blood, which is positively correlated with age and fat mass index
Arana Echarri A, Struszczak L, Beresford M, Campbell JP, Jones RH, Butler R, Thompson D, Turner JE. University of Bath, Bath, United Kingdom; Royal United Hospitals Bath NHS Trust, Bath, United Kingdom; Velindre Cancer Centre and Cardiff University, Cardiff, United Kingdom; South West Genomics Laboratory Hub, North Bristol NHS Trust, Bristol, United Kingdom.
P1-04-11 Pd-l1-expressing b-cells promote murine breast cancer development and mediate the response to anti-pd-l1 immune checkpoint inhibitor
Khan MTA, Cervantes C, Viswanadhapalli S, Hui Y, Vadlamudi R, Xu Z. University of Texas Health San Antonio, San Antonio, TX.
P1-04-12 Pathway analysis of immune checkpoint gene regulation as altered in Type 2 diabetes: Implications for breast cancer patients treated with checkpoint inhibitors
Ennis CS, LLevenes P, Kolla M, Jafari N, Belkina AC, Denis GV. Boston University, Boston, MA.
P1-04-13 Generation and validation of an estrogen receptor signaling (ERS) gene panel that inversely correlates with antigen presentation and T cell infiltration and activity in hormone receptor positive (HR+) breast cancer
Goldberg JS, Cui X, Shimada K, McAllister S, Tolaney S, Waks A, Jeselsohn R, Guerriero J, Agudo J, Mittendorf E. Dana-Farber/ Brigham and Womens Cancer Center, Boston, MA; Brigham and Women's Hospital, Boston, MA.
   
  Tumor Cell and Molecular Biology: Tumor Heterogeneity/Molecular Subclassification
P1-05-01 The tumor immune microenvironment and HER2 landscape of high-risk ductal carcinoma in situ: The DEFENSE study
Glencer A, Borowsky A, Mori H, Campbell M, Harismendy O, Stein J, Ghule P, Evans M, West R, Hirst G, Schindler N, Miller P, Lee K, Weaver D, Esserman L. University of California San Francisco, San Francisco, CA; University of California Davis, Sacramento, CA; University of California San Diego, San Diego, CA; University of Vermont, Burlington, VT; Stanford University, Palo Alto, CA.
P1-05-02 Intratumor molecular tumor heterogeneity in low ER-expressing primary breast tumors
Foldi J, Reisenbichler E, Pan L, Sorg K, Church SE, Pusztai L. Yale University School of Medicine, New Haven, CT; NanoString Inc, Seattle, WA.
P1-05-03 Integrating spatial transcriptomics and high-resolution morphological annotation to investigate tumor heterogeneity and PAM50 molecular subtyping in lobular breast cancer
Serra M, Collet L, Rediti M, Lifrange F, Venet D, Wang X, Vincent D, Rouas G, Fimereli D, Gacquer D, Joaquin Garcia A, Veys I, Craciun L, Larsimont D, Vikkula M, Duhoux F, Rothé F, Sotiriou C. Breast Cancer Translational Research Laboratory J-C Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Laboratoire d'Anatomie Pathologique, Institut Jules Bordet, Université libre de Bruxelles, Brussels, Belgium; Department of Surgery, Institut Jules Bordet, Université libre de Bruxelles, Brussels, Belgium; Human Molecular Genetics, de Duve Institute, Université Catholique de Louvain, Brussels, Belgium; Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium.
P1-05-04 Novel breast cancer proteomic subtyping with connection to cell of origin
Wang G, Shah P, Searfoss R, Fantacone-Campbell JL, Hooke JA, Deyarmin B, Zingmark RN, Somiari S, Liu J, Kvecher L, Sturtz LA, Raj-Kumar P-K, Granger E, Vahdat L, Narain NR, Cutler ML, Sarangarajan R, Hu H, Kiebish MA, Kovatich AJ, Shriver CD. Murtha Cancer Center / Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD; BERG LLC, Framingham, MA; Chan Soon-Shiong Institute of Molecular Medicine at Windber, Windber, PA; Memorial Sloan Kettering Cancer Center, New York, NY; Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, MD; Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD.
P1-05-05 Prognostic value of HER2 expression levels in non-metastatic triple-negative breast cancer and correlation with other biomarkers
Jacot W, Maran-Gonzales A, Massol O, Sorbs C, Mollevi C, Guiu S, Boissière-Michot F, Ramos J. Institut du Cancer de Montpellier, Montpellier, France.
P1-05-06 Establishment of novel BRCA1ness score to quantify BRCAness in breast cancer
Oshi M, Wu R, Yamada A, Yan L, Ishikawa T, Endo I, Takabe K. Roswell Park Comprehensive Cancer Institute, Buffalo, NY; Yokohama City University Graduate School of Medicine, Yokohama, Japan; Tokyo Medical University, Tokyo, Japan.
P1-05-07 Spatially-resolved single-cell tumor heterogeneity captured by TumorScope biophysical modeling software using MR Imaging
Cook DJ, Whitman J, Liadis N, Cole J. SimBioSys, Inc., Champaign, IL.
P1-05-08 Withdrawn
P1-05-09 Analysis of immunophenotyping of patient-derived primary breast cancer cells according to the medium composition and culture method
Seungyeon RYU, Hoe Suk Kim, So-Hyun Yoon, Sangeun Lee, Junhyuk Song, Moonjou Baek, , Han-Byoel Lee, Sangyong Jon and Wonshik Han. Cancer Research Institute, Seoul National University, Biomedical Research Institute, Seoul National University Hospital, Interdisciplinary Programs in Cancer Biology Major, Seoul National University Graduate School, Korea, Republic of Cancer Research Institute, Seoul National University, Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea, Republic of Cancer Research Institute, Seoul National University, Biomedical Research Institute, Seoul National University Hospital, Interdisciplinary Programs in Cancer Biology Major, Seoul National University Graduate School, Seoul, Korea, Republic of Cancer Research Institute, Seoul National University, Biometitute, Seoul National University Hospital, Interdisciplinary Programs in Cancer Biology Major, Seoul National University Graduate School Integrated Major in Innovative Medical Science, Seoul Nati, Seoul, Korea, Republic of Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Korea, Daejeon, Korea, Republic of Department of Surgery, Seoul National University College of Medicine, Cancer Research Institute, Seoul National University Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea, Republic of Cancer Research Institute, Seoul National University, Seoul, Republic of Korea.
   
  Tumor Cell and Molecular Biology: Tumor Progression, Invasion, and Metastasis
P1-06-01 Insights from rapid autopsy shed light on mechanisms of cancer dissemination in metastatic breast cancer
Bacon ER, Ihle K, Egelston C, Guo W, Simons D, Schmolze D, Wei C, Tumyan L, Lee PP, Waisman JR. City of Hope, Duarte, CA.
P1-06-02 Targeted deletion of Kindlin-2 in mouse mammary glands inhibits tumor growth, invasion and metastasis downstream of TGF-β/EGF oncogenic signaling pathway
Rana P, Wang W, Alkrekchi A, Bialkowska K, Markovic V, Plow EF, Pluskota E, Sossey-Alaoui K. Case Western Reserve University, Cleveland, OH; MetroHealth Medical Center, Cleveland, OH; Cleveland Clinic Lerner Research Institute, Cleveland, OH.
P1-06-03 Promotion of E-cadherin-mediated tumor cell adhesion by COX-2/ GSK3β signaling is a targetable mechanism of metastatic breast cancer
Balamurugan K, Sehareen S, Krishnamurthy S, Sharan S, Tang W, Ueno N, Ambs S, Poria D, Sterneck E. NCI, Frederick, MD; Morgan Welch Inflammatory Breast Cancer Research Program, MDACC, Houston, TX; NCI, Bethesda, MD.
P1-06-04 Spatial, temporal and therapy dependent heterogeneity in transport phenotype of multiple liver metastases in murine breast cancer model
Nguyen T, Liu Yt, Ziemys A, Haifa S, Yokoi K. Houston Methodist Research Institute, Houston, TX.
P1-06-05 Cd73 may influence zoledronate-induced b- and t-cell accumulation into triple-negative breast tumors
Petruk N, Siddiqui A, Määttä J, Sandholm J, Selander K. University of Turku, Institute of Biomedicine, Turku, Finland; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland; Oulu University Hospital, Oulu, Finland.
P1-06-06 Withdrawn
P1-06-07 Enhanced differentiation of clinical behavior by breast carcinomas utilizing quantification of estrogen and progestin receptor proteins and gene expression subsets
Wittliff JL, Daniels MW. University of Louisville, School of Medicine, Louisville, KY; University of Louisville, School of Public Health, Louisville, KY.
P1-06-08 Metabolic diversity determines metastatic fitness of breast cancer brain-tropic cells
Malladi S. UT Southwestern Medical Center, Dallas, TX.
P1-06-09 The role of miR-155-5p in MSI2 induced metastasis of prolonged DEHP exposed triple-negative breast cancer cells
Jadhao MG, Chiu CC. Kaohsiung Medical University, Kaohsiung, Taiwan.
   
  Prognostic and Predictive Factors: Predictive Biomarkers for Endocrine Therapies
P1-07-01 Real time detection of ESR1 mutation in blood by droplet digital PCR in the PADA-1 trial: Feasibility and cross-validation with NGS
Callens C, Bidard F-C, Curto-Taribo A, Trabelsi-Grati O, Melaabi S, Delaloge S, Hardy-Bessard A-C, Bachelot T, Clatot F, De La Motte Rouge T, Canon J-L, Arnould L, André F, Marques S, Stern M-H, Pierga J-Y, Salomon A-V, Jeannot E, Berger F, Bieche I, Pradines A. Institut Curie, Paris, France; Gustave Roussy, Villejuif, France; CARIO - Centre Armoricain Radiothérapie Imagerie Médicale et Oncologie, Plérin, France; Centre Léon Bérard, Lyon, France; Centre Henri Becquerel, Rouen, France; Centre Eugène Marquis, Rennes, France; Grand Hôpital de Charleroi, Charleroi, Belgium; Centre Georges François Leclerc, Dijon, France; UNICANCER, Paris, France; Institut Claudius Régaud, Toulouse, France.
P1-07-02 Primary results of ONAWA (SOLTI-1802) trial: A window of opportunity trial of onapristone in postmenopausal women with progesterone receptor-positive/HER2-negative early breast cancer (EBC)
Bellet M, Morales S, Gasol A, Amillano K, Chic N, González-Farré X, Villagrasa P, Paré L, Falato C, Nuciforo P, Martínez D, Ferrero-Cafiero JM, Pascual T, Prat A, Lange C, Saura C. SOLTI Breast Cancer Research Group / Medical Oncology Department, Vall d'Hebron University Hospital / Breast Cancer Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; Medical Oncology Department, Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Medical Oncology Department, Hospital Universitari Sant Joan de Reus, Reus, Spain; Medical Oncology Department, Hospital Clínic de Barcelona, Barcelona, Spain; SOLTI Breast Cancer Research Group / Medical Oncology Department, Hospital General de Catalunya, Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; SOLTI Breast Cancer Research Group / Medical Oncology Department, Hospital Clínic de Barcelona, Barcelona, Spain; Molecular Oncology Group, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors Lab, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; SOLTI / Medical Oncology Department, Hospital Clínic de Barcelona / Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain; Departments of Medicine (Division of Hematology, Oncology, and Transplantation) and Pharmacology and The Masonic Cancer Center, University of Minnesota, Minneapolis, MN.
P1-07-03 Clinical treatment score post-5 years (CTS5) and the prediction of survival benefit from extended endocrine therapy for breast cancer patients under and over 50 years of age
Ahn JH, Park JM, Choi SB, Go J, Kim JY, Park HS, Kim SI, Park B-W, Park S. Yonsei University College of Medicine, Seoul, Republic of Korea.
P1-07-04 Potential role of the antibody-dependent cellular phagocytosis (ADCP) in tumors achieving pCR in NRG Oncology/NSABP B-52
Pogue-Geile KL, Wang Y, Feng H, Lipchick C, Gavin P, Kim RS, Cecchini RS, Jacobs SA, Srinivasan A, Swain SM, Mamounas E, Geyer, Jr CE, Rastogi P, Lucas PC, Osborne CK, Paik S, Wolmark N, Rimawi MF. NSABP/NRG Oncology, Pittsburgh, PA; NSABP/NRG Oncology, and AstraZeneca, Oncology Translational Medicine, Gaithersburg, MD; NSABP/NRG Oncology, and The University of Pittsburgh, Pittsburgh, PA; NSABP/NRG Oncology, and Autism Impact Fund, Pittsburgh, PA; NSABP/NRG Oncology, and Georgetown University Lombardi Comprehensive Cancer Center, MedStar Health, Washington, DC, DC; NSABP/NRG Oncology, and Houston Methodist Cancer Center, Pittsburgh, PA; NSABP/NRG Oncology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, and Magee-Womens Hospital, Pittsburgh, PA; NSABP/NRG Oncology, and UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA; NSABP/NRG Oncology, and Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, TX; NSABP/NRG Oncology, and Yonsei University College of Medicine, Seoul, Republic of Korea; NSABP/NRG Oncology and UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA.
P1-07-05 Gene expression analysis of HOXB13-high and -low tumors reveals a dichotomous immune landscape
Lachtara E, Lawrence M, Sgroi D. Harvard Medical School, Boston, MA; Harvard Medical School, Winchester, MA.
P1-07-06 Endoxifen exposure after 5 weeks of preoperative tamoxifen is predictive of long-term outcome of operable hormone receptor positive (HR+) HER2 - early breast cancer
Frenel J-S, Campion L, Schmitt A, De Cremoux P, Rossignol E, Renaudeau C, Robert M, Bard J-M, Bobin-Dubigeon C, Campone M. Institut de Cancerologie de L'Ouest, Saint- Herblain, France; Centre Georges-Francois Leclerc, Dijon, France; Hopital Saint Louis, Paris, France.
P1-07-07 Endoresist: prognostic and predictive gene profiles in endocrine-resistant breast cancers
Schagerholm C, Robertson S, Holm B, Lindberg K, Sifakis E, Hases L, Williams C, Hartman J. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institutet and Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden; Novartis Sverige AB, Kista, Sweden; Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden; Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab and Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institutet and Department of Clinical Pathology and Cancer Diagnostics, and MedtechLabs Bioclinicum, Karolinska University Hospital, Stockholm, Sweden.
P1-07-08 Endoxifen predicts early recurrence in breast cancer: A Brazilian prospective study
Almeida T, Schroth W, Nardin JM, Mürdter T, Picolotto S, Hoppe R, Kogin JP, Gaio ED, Dasenbrock A, Skrsypcsak RC, Noronha L, Brauch H, Casali-da-Rocha JC. Hospital Erasto Gaertner, Curitiba, Brazil; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; Pontifical Catholic University of Parana, Curitiba, Brazil.
P1-07-09 Results of treatment with inhibitors of cycline-dependent kinase CDK4/6 in patients with breast cancer in the presence of different types mutation in the PIK3CA gene
Sultanbaev A, Nasretdinov A, Menshikov K, Musin S, Sultanbaeva N. Republican Clinical Oncological Center, Ufa, Russian Federation.
P1-07-10 Estrogen-stimulated DNA damage in mammary epithelium varies among strains of rodents and women
Dunphy KA, Sharma A, Majhi P, Schneider SS, Crisi GM, Makari-Judson G Jerry DJ. University of Massachusetts & Pioneer Valley Life Sciences Institute, Amherst, MA; University of Massachusetts-Amherst, Amherst, MA; University of Massachusetts Medical Center-Baystate & Pioneer Valley Life Sciences Institute, Springfield, MA; University of Massachusetts Medical Center-Baystate, Springfield, MA.
   
  Prognostic and Predictive Factors-Biomarkers Predicting Tx Response:Predictive Biomarkers for Chemo
P1-08-01 Validation of automated Ki67 analysis to predict Oncotype DX recurrence score in early-stage breast cancer
Chan AMY, Abedin T, Thakur S, Li H, Konno M, Enwere E, Lupichuk S, Nixon N, Morris D, Yang H, Neri P. Alberta Health Services, Calgary, AB, Canada; University of Calgary, Calgary, AB, Canada.
P1-08-02 Cytochrome P450 reductase gene, POR, associated with paclitaxel induced peripheral neuropathy in patients of European ancestry from the adjuvant breast cancer trial, ECOG-ACRIN E5103
Shen F, Jiang G, Gardner L, Xue G, Philips S, Ly R, Wilberforce O, Wu X, Cantor E, Dang C, Northfelt D, Skaar T, Miller KD, Sledge G, Schneider BP. Indiana University School of Medicine, Indianapolis, IN; Memorial Sloan Kettering Cancer Center, New York, NY; Mayo Clinic, Phoenix, AZ; Stanford University, Palo Alto, CA.
P1-08-03 Deep learning for early prediction of neoadjuvant chemotherapy response in triple negative breast cancers
Zhou Z, Elshafeey NA, Rauch DE, Adrada BE, Candelaria RP, Guirguis MS, Yang W, Boge M, Mohamed RM, Whitman GJ, Lane DL, Le-Petross HC, Leung JWT, Santiago L, Scoggins ME, Spak DA, Patel MM, Perez F, Tripathy D, Valero V, Yam C, Moulder S, White JB, Son JB, Pagel MD, Ma J. The University of Texas MD Anderson Cancer Center, Houston, TX.
P1-08-04 The impact of sarcopenia and sarcopenic obesity detected by bioelectrical impedance analysis in patients with early breast cancer
Aleixo GFP, Wei W, Valente SA, Moore HCF. Cleveland Clinic Foundation, Cleveland, OH.
P1-08-05 Expression of the human APOE4 genotype modulates Doxorubicin cardiotoxicity in mice
Wang G, Rebeck GW, Rodriguez O, Lippman ME, Bishopric NH. Georgetown Lombardi Comprehensive Cancer Center, Washington, DC.
P1-08-06 Development of an aritifical neural network model and comparison with nomogram for prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer
Shin H-C, Jung J-J, Kim E-K, Kang E. Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
P1-08-07 Prediction model of the response of neoadjuvant chemotherapy and long term survival according to multi-omic profiling in cooperation with clinicopathologic features in patients with breast cancer
Kim J-Y, Park K, Park W-Y, Lee JE, Kim SW, Nam SJ, Lee SK, Kan Z, Park YH. Samsung Medical Center, Seoul, Republic of Korea; Samsung Genome Institute, Seoul, Republic of Korea; Oncology Research & Development, Pfizer, San Diego, CA.
P1-08-08 Forecasting treatment response to neoadjuvant systemic therapy in triple negative breast cancer <i>via</i>mathematical modeling and quantitative MRI
Wu C, Jarrett AM, Zhou Z, Elshafeey N, Adrada BE, Candelaria RP, Mohamed RM, Boge M, Huo L, White J, Tripathy D, Valero V, Litton J, Moulder S, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TE. The University of Texas at Austin, Austin, TX; The University of Texas MD Anderson Cancer Center, Houston, TX; Eli Lily and Company, Indianapolis, IN.
P1-08-09 High mid-treatment RNA disruption in patients with HER2-negative breast cancer predicts survival benefit after neoadjuvant chemotherapy
Pritzker LB, Haugland Haugen M, von der Lippe Gythfeldt H, Masilamani T, Theriault G, St-Onge R, D'costa L, Lingjaerde OC, Parissenti A, Engebraaten O. Rna Diagnostics, Toronto, ON, Canada; Institute for Cancer Research, The Norweigan Radium Hospital, Oslo University Hospital, Oslo, Norway; Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Rna Diagnostics, Sudbury, ON, Canada; Laurentian University, Sudbury, ON, Canada; Oslo University Hospital, Oslo, Norway.
P1-08-10 Ki67 assessment based on international Ki67 working group recommendations and correlation with 21-gene assay results in a large integrated health care system: We might not be there yet
Shim VC, Baker RJ, Jing W, Agersborg SS, Lee TK, Goreal W, Achacoso N, Lee C, Villasenor M, Lin A, Kapali M, Habel LA. The Permanente Medical Group, Oakland, CA; The Permanente Medical Group, San Francisco, CA; The Permanente Medicine, San Francisco, CA; NeoGenomics Laboratories, Inc., Aliso Viejo, CA; The Permanente Medical Group, Division of Research, Oakland, CA; The Permanente Medical Group, Sacramento, CA.
P1-08-11 Clinical relevance of host immunity in patients with breast cancer who received neoadjuvant chemotherapy
Bae SJ, Ji JH, Chu C, Yoon Jin Cha, Kim JH, Ahn SG, Jeong J. Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
P1-08-12 The status of homologous recombination deficiency is a potential biomarker for platinum-based chemotherapy in triple-negative breast cancer
Chen Y, Wang X, Du F, Yue J, Si Y, Cui L, Zhang B, Xu B, Yuan P. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Department of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), The VIPII Gastrointestinal Cancer Division of Medical Department, Peking University Cancer Hospital and Institute, Beijing, China; The Medical Department, 3D Medicines Inc., Shanghai, China.
P1-08-13 Comparison of gene expression profiling results and clinical outcomes among patients with pleomorphic ILC and classic ILC
Dempster M, Wright M, Cocco D, Elsherif A, Valente SA, Li H, Kruse ML. Cleveland Clinic Foundation, Cleveland, OH.
P1-08-14 Differences in Recurrence Score (RS) results between primary and second primary breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS) registry
Strulov Shachar S, Leviov M, Yerushalmi R, Drumea K, Tokar M, Soussan-Gutman L, Bareket-Samish A, Sonnenblick A, Efrat Ben-Baruch N, Paluch-Shimon S, Bar Sela G, Stemmer SM. Sourasky Medical Center, Tel Aviv, Israel; Lin Medical Center, Haifa, Israel; Davidoff Center, Rabin Medical Center, Petah Tikva, Israel; Rambam Health Care Campus, Haifa, Israel; Soroka University Medical Center, Beer Sheva, Israel; Oncotest- Rhenium, Modi'in, Israel; BioInsight Ltd, Binyamina, Israel; Kaplan Medical Center, Rehovot, Israel; Hadassah Hebrew University Medical Center, Jerusalem, Israel; Emek Medical Center, Afula, Israel.
P1-08-15 Communication between tumor cells and fibroblasts as a prognostic factor of NACT in TNBC
Bauer M, Vetter M, Maia A, Vlachavas E, Michels B, Berdiel-Acer M, Schüler K, Morselli A, Skarlatou M, Thomssen C, Wiemann S. Institute of Pathology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany; Dept. of Gynecology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany.
P1-08-16 Using machine learning approaches to predict response to neoadjuvant chemotherapy in patients with triple-negative breast cancer
Fisher TB, Li H, TS R, Krishnamurthy J, Bhattarai S, Janssen EAM, Kong J, Aneja R. Georgia State University, Atlanta, GA; JSS Medical College, Karnataka, India; Stavanger University and Stavanger University Hospital, Atlanta, GA.
P1-08-17 Melk expression is associated with immune cell infiltration and pathological compete response (pcr) after neoadjuvant chemotherapy in breast cancer
Oshi M, Gandhi S, Huyser MR, Tokumaru Y, Yan L, Wu R, Yamada A, Endo I, Takabe K. Roswell Park Comprehensive Cancer Center, Buffalo, NY; Yokohama City University Graduate School of Medicine, Yokohama, Japan.
P1-08-18 Impact of gene expression profile testing for lymph node positive (LN+) , hormone receptor positive (HR+), HER2 negative (HER2-) breast cancer (BC) patients on the use of adjuvant chemotherapy in a large community cancer center
Kalmadi NR, Brown A, Sharma M, Shtivelband M, Rifkind J, Kalmadi S, Bagai R, Ho E, Clark P, Kellogg C, Khanuja P. Arizona State University, Tempe, AZ; Arizona College of Osteopathic Medicine, Midwestern University, Mesa, AZ; Rensselaer Polytechnic institute, Troy, NY; Ironwood Cancer Center, Chandler, AZ.
P1-08-19 Utilising artificial intelligence (AI) for analysing multiplex genomic and magnetic resonance imaging (MRI) data to develop multimodality predictive system for personalised neoadjuvant treatment of breast cancer (BC)
Abdel-Fatah TM, Ball G, Chen X, Mehaisi D, Giannotti E, Auer D, Vadakekolathu J, Li R, Pockley G, Chan S. Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Nottingham Trent University, Nottingham, United Kingdom; University of Nottingham, Nottingham, United Kingdom.
P1-08-20 In silico analysis of a novel mathematical model integrating in vitro and in vivo imaging data reveals driving mechanisms of breast cancer response to NAT for personalized tumor forecasting
Lorenzo G, Jarrett AM, Meyer CT, Tyson DR, Quaranta V, Yankeelov TE. The University of Texas at Austin, Austin, TX; Vanderbilt University, Nashville, TN.
P1-08-21 Assessing the impact of treatment interruptions during neoadjuvant therapy in early stage breast cancer
Pandey T, Pfeiffer JR, Braun E, Abe H, Howard F, He G, Pearson AT, Nanda R. SimBioSys, Inc., Chicago, IL; Michiana Hematology Oncology, Westville, IN; Department of Radiology, The University of Chicago, Chicago, IL; Department of Medicine, University of Chicago, Chicago, IL.
P1-08-22 The role of DAXX as a critical growth regulator of triple negative breast cancer
Osipo C, Wyatt D, Fernandez M, Peiffer DS, Albain KS. Loyola University Chicago, Maywood, IL; Loyola University Stritch School of Medicine, Maywood, IL.
P1-08-23 Androgen receptor as predictive marker for pathologic complete response in breast cancer with neoadjuvant chemotherapy
Lee E-G, Lee D-E, Han JH, Lee S, Kang H-S, Lee ES, Kwon Y, Kim HH, Chae HJ, Sim SH, Lee KS, Jung S-Y. National Cancer Center, Goyang, Republic of Korea.
P1-08-24 Platelet-to-lymphocyte ratio is worth using with tumor-infiltrating lymphocytes to predict good response to neoadjuvant chemotherapy in triple negative breast cancer: A study on 120 patients
Radosevic-Robin N, Lusho S, Durando X, Mouret-Reynier M-A, Kossai M, Lacrampe N, Molnar I, Penault-Llorca F, Abrial C. University Clermont Auvergne, INSERM U1240, Centre Jean Perrin, Department of Pathology, Clermont-Ferrand, France; University Clermont Auvergne, INSERM U1240, Centre Jean Perrin, Department of Clinical Research, Clermont-Ferrand, France; University Clermont Auvergne, INSERM U1240, Centre Jean Perrin, Department of Oncology, Department of Clinical Research, Clermont-Ferrand, France; University Clermont Auvergne, INSERM U1240, Centre Jean Perrin, Department of Oncology, Clermont-Ferrand, France.
P1-08-25 Evaluating an ex vivo organ culture system for predicting response to neoadjuvant chemotherapy in breast cancer patients
Gal-Yam EN, Sklair-Levi M, Vachnish Y, Balint-Lahat N, Morzaev-Sulzbach D, Bakalenik-Gavry M, Fearmann R, Halshtok O, Shalmon A, Gotlieb M, Yagil Y, Levanon K, Bernstein-Molho R, Itay A, Shapira-Rotenberg T, Globus O, Barshack I, Salpeter S, Bar V, Aharon S, Turovsky L, Zundelevich A, Mallel G, Shahar H, Shapira H, Dadiani M. Sheba Medical Center, Ramat Gan, Israel; Curesponse, Rehovot, Israel.
P1-08-26 Morphologic characterization of tumor-infiltrating lymphocytes and its relation with pathological response in a series of breast cancer patients treated with primary chemotherapy
Falo C, Azcarate J, Petit A, Vethencourt A, Fernandez Gonzalez S, Garcia-Tejedor A, Vazquez S, Perez H, Laplana M, Taco C, Guerra E, Guma A, Ortega R, Stradella A, Recalde S, Fernandez-Ortega A, Villanueva R, Perez FJ, Pla MJ, Campos M, Perez D, Fernandez-Montoliu E, Obadia V, Cejuela M, Gil-Gil M, Pernas S, Varela M, Soler-Monzo T. Institut Catala d'Oncologia, Barcelona, Spain; Hospital Universitari Bellvitge. Breast Cancer Unit, Barcelona, Spain; Hospital Universitari Bellvitge., Barcelona, Spain.
P1-08-27 Dynamic monitoring of circulating tumor DNA can predict chemotherapy response and prognosis in metastatic triple-negative breast cancer patients
Li H, Chi Y, Yin S, Yu B, Su M, Zhang B, Qiang L, Ren G, Song L, Bu B, Fang S, Shang M, Tan Q, Man X. Shandong Cancer Hospital and Institute, Jinan, China; Berry Oncology Corporation, Beijing, China; Jinan Central Hospital, Jinan, China.
P1-08-28 Real world use of OncotypeDx testing in the management of breast cancer. The North East England experience
Gault A, Veeratterapillay J, Taylor W. Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.
P1-08-29 The influence of pre-treatment peripheral blood inflammatory markers on post-treatment response in patients with locally advanced breast cancer (LABC) from Saudi Arabia
Abusanad A, Alghamdi AM, Saggaf AM, Gazzaz T, Brika R. King Abdulaziz University, Jeddah, Saudi Arabia.
P1-08-30 Validation of the AAGAB gene as a novel on-treatment biomarker predicting pCR in patients receiving NACT for early breast cancer
Semple F, Ironside A, Bownes R, Martinez-Perez C, Wilson N, Turnbull A, Oikonomidou O. University of Edinburgh, Edinburgh, United Kingdom; Western General Hospital, Edinburgh, United Kingdom.
P1-08-31 Simbiosys tumorscope: Biophysical modeling of patient-specific response to chemotherapy
Cole, Jr., JA Peterson JR, Earnest TM, Hallock MJ, Cook DJ, Braun E, Antony A, Pfeiffer JR, Pandey T. SimBioSys Inc., Champaign, IL.
P1-08-32 Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in patients with early-stage triple-negative breast cancer: A meta-analysis
Chen Y, Zhang L, Cheng M, Zhuang X, Yang C-O, Ji F, Gao H-F, Yang M, Zhu T, Li J, Wang K. Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
P1-08-33 Disparities in the practice of precision medicine? Using multi-gene testing in early-stage, HR+/HER2- breast cancer
Nadeem Bilani, Marita Yaghi, Diana Saravia, Iktej Jabbal, Maroun Bou Zerdan, Leah Elson, Liang Hong and Zeina Nahleh. Icahn School of Medicine, Mount Sinai Morningside and West, New York, NY;Cleveland Clinic Florida, Weston, FL.
P1-08-34 Peripheral immunity predicts therapeutic outcomes in breast cancer patients
Margaret L Axelrod, Yu Wang, Yaomin Xu, Cosmin A. Bejan, Xiaopeng Sun, Paula I Gonzalez-Ericsson, Riley E Bergman, Joshua Donaldson, Sara Nunnery, Melinda Sanders, Chiara Massa, Barbara Seliger, Ingrid A Mayer and Justin M Balko. Vanderbilt University, Nashville, TN;Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
P1-08-35 Stromal tumor infiltrating lymphocytes analysis by race and ethnicity in triple negative breast cancers from 2 phase III randomized adjuvant breast cancer trials: ECOG-ACRIN E2197 and E1199
Klar N, Gray RJ, Adams S, Sparano JA, Goldstein LJ, DeMichele AM, Wolff AC, Davidson NE, George W Sledge GW, Badve SS. Laura and Isaac Perlmutter Cancer Center at NYU Langone Grossman School of Medicine, New York, NY; Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, MA; The Tisch Cancer Institute at Mount Sinai, New York, NY; Fox Chase Cancer Center, Philadelphia, PA; University of Pennsylvania/Abramson Cancer Center, Philadelphia, PA; Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, MD; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA; Stanford Cancer Institute Palo Alto, Stanford, CA; Emory Winship Cancer Institute, Atlanta, GA.
P1-08-36 Racial disparity in post-neoadjuvant chemotherapy residual breast tumor microenvironment
Kim G, Asiry S, Oktay I, Lin Y, Ye X, Cheng E, Ladak N, Condeelis J, Adler E, Ginter P, D'Alfonso T, Entenberg D; Oktay m. Montefiore Medical Center, Bronx, NY; University of Colorado, Boulder, CO; Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY; New York Presbyterian/Weill Cornell Medical Center, New York, NY; NYU Langone Health, New York, NY; Memorial Sloan Kettering Cancer Center, New York, NY.
   
  Epidemiology, Risk, and Prevention: Prevention - Nutritional Studies
P1-09-01 Breast and prostate cancer risk associated with nitrites and nitrates from food additives: Results from the NutriNet-Santé cohort
Chazelas E, Pierre F, Druesne-Pecollo N, Esseddik Y, Szabo de Edelenyi F, Agaesse C, De Sa A, Lutchia R, Gigandet S, Srour B, Debras C, Huybrechts I, Julia C, Kesse-Guyot E, Allès B, Zelek L, Galan P, Hercberg S, Deschasaux-Tanguy M, Touvier M. Sorbonne Paris Nord University, Inserm U1153, Inrae U1125, Cnam, Nutritional Epidemiology Research Team (EREN), Epidemiology and Statistics Research Center – University of Paris (CRESS), Bobigny, France; Toxalim (Research Centre in Food Toxicology), Université de Toulouse, INRAE, ENVT, INP-Purpan, UPS, Toulouse, France, Toulouse, France; Open Food Facts, Saint-Maur-des-Fossés, France; International Agency for Research on Cancer, World Health Organization, Lyon, France.
P1-09-02 Risk of breast and other cancers associated with the consumption of artificial sweeteners: Results from the prospective NutriNet-Santé cohort
Debras C, Chazelas E, Srour B, Druesne-Pecollo N, Essedik Y, Szabo de Edelenyi F, Agaësse C, De Sa A, Lutchia R, Gigandet S, Huybrechts I, Julia C, Kesse-Guyot E, Zelek L, Allès B, Andreeva VA, Galan P, Hercberg S, Deschasaux-Tanguy M, Touvier M. Nutritional epidemiology Research Team (Inserm, Inra, Cnam, Paris 13 University), Bobigny, France; Open Food Facts, Saint-Maur-des-Faussés, France; International Agency for Research on Cancer, World Health Organization, Lyon, France; Oncology Department, Avicenne Hospital, AP-HP, Bobigny, France.
P1-09-03 Omega-3 polyunsaturated fatty acid supplementation shifts the gut and breast microbiome to influence inflammation
Cook KL, Wilson AS, Soto-Pantoja DR, Kimler BF, Umar S, Fabian CJ. Wake Forest University School of Medicine, Winston Salem, NC; University of Kansas Medical Center, Kansas City, KS.
P1-09-04 Flaxseed & breast cancer: A systematic review
Wang R, Yang M, Zhi I, Bao T. Memorial Sloan Kettering Cancer Center, Montvale, NJ; Memorial Sloan Kettering Cancer Center, New York, NY.
P1-09-05 Baseline dietary patterns among women with newly diagnosed early-stage breast cancer enrolled in the Optimal Living Program
Shen S, Allsop J, Salehi E, Anselmo C, Corcoran S, Clayton J, Smith A, Emerzian M, Robson M, Iyengar N. Memorial Sloan Kettering Cancer Center, New York, NY.
P1-09-06 Insulinemic potential of diet and risk of total and subtypes of breast cancer among US women
Romanos-Nanclares A, Willett WC, Rosner BA, Tamimi RM, Tabung FK, Holmes MD, Chen WY, Eliassen AH. Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Weill Cornell Medicine, New York, NY; The Ohio State University College of Medicine, Columbus, OH; Dana-Farber Cancer Institute, Boston, MA.
   
  Epidemiology, Risk, and Prevention: Prevention - Clinical Trials
P1-10-01 Results from the breast cancer - anti progestin prevention study 1 (BC-APPS1) trial - a novel approach in breast cancer prevention
Howell S, Greenhalgh A, Pedley R, Alghamdi S, Caruso A, Ansari M, Moreira T, Astlet S, Maxwell A, Lim Y, Brookes H, Idries F, Howell A, Evans DG, Sherratt M, Gilmore A, Harkness E, Khaled W, Twigger A-J, Roberts M, Clarke R, Simoes B. University of Manchester, Manchester, United Kingdom; Manchester University NHS Foundation Trust, Manchester, United Kingdom; University of Cambridge, Cambridge, United Kingdom.
P1-10-02 Effect of metformin on metabolic markers associated with breast cancer risk in a phase II clinical trial in overweight/obese premenopausal women
Tapia E, Villa-Guilen D, Chalasani P, Centuori S, Roe DJ, Guillen J, Cordova C, Pinto L, Chow S. University of Arizona Cancer Center, Tucson, AZ; Universidad de Sonora, Hermosillo, Mexico; Department of Epidemiology and Biostatistics, University of Arizona, Tucson, AZ.
P1-10-03 Estrogen and breast cancer benefits: Emerging hormone replacement therapy breast cancer paradigms
Ragaz J, Spinelli JJ, Qian H, Won H, Shakeraneh S, Fox J, Wilson KS. School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada; Institute on Aging & Lifelong Health, University of Victoria, Delta, BC, Canada; Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; British Columbia Cancer, Victoria, BC, Canada. .
P1-10-04 AGR2, an estrogen response gene associated with tamoxifen resistance, is modulated by acolbifene in premenopausal women at high risk for development of breast cancer
Fabian CJ, Phillips TA, Kimler BF. University of Kansas Medical Center, Kansas City, KS.
P1-10-05 Evidence that body mass index modifies breast tissue collagen peptide response pattern to treatment with the non-steroidal anti-inflammatory drug sulindac
Rujchanarong D, Angel PM, Stopeck A, Preece C, Chalasani P, Thompson PA. Medical University of South Carolina, Charleston, SC; Stony Brook Cancer Center, Stony Brook, NY; Cedars Sinai, Los Angeles, CA; University of Arizona Cancer Center, Tucson, AZ.
P1-10-06 Effect of aging and mTOR inhibition on human mammary stem cells and early breast cancer progression markers
Broome LE, Bouamar H, Lathrop K, Jatoi I, Brenner A, Garcia M, Nazarullah A, Moncada K, Kaklamani V, and Sun L-Z. University of Texas Health Science Center San Antonio, San Antonio, TX.
P1-10-07
A randomized, controlled, 2x2 factorial trial of a diet and physical activity intervention among Latina breast cancer survivors: ¡Mi Vida Saludable! study

Greenlee H, Santiago-Torres M, Koch P, Tsai W-Y, Gray HL, Brickman AM, Ogden Gaffney A, Eddy M, Thomson CA, Crane TE, Dominguez N, Sepulveda J, Marin-Chollom AM, Paul R, Shi Z, Ulanday KT, Shen H, Castellano M, Fuentes Y, Crew K, Kalinsky K, Accordino M, Trivedi M, Taback B, Beauchemin M, Camacho FJ, Friedman DT, Contento I, Hershman DL. Fred Hutchinson Cancer Research Center, Seattle, WA; Columbia University, New York, NY; University of South Florida, Tampa, FL; Cook For Your Life, New York, NY; Moving for Life, New York, NY; University of Arizona, Tucson, AZ; Eat Good Consulting, Inc., New York, NY; Montefiore, Bronx, NY.
   
  Epidemiology, Risk, and Prevention: Prevention - Preclinical Studies and Model Systems
P1-11-01 Modulation of the high risk postmenopausal breast tissue genomic profiles with licorice and its bioactive compounds
Hajirahimkhan A, Chen S-N, Pauli GF, Bartom E, Clare S, Khan SA. Northwestern University, Chicago, IL; University of Illinois at Chicago, Chicago, IL.
P1-11-02 Parity reduces the risk of mammary cancer by altering the characteristics of mammary stem cells
Subramani R, Estrada A, Rodriguez S, Poudel S, Foskey J, Jimenez C, Smith K, Shahinian M, Yazadi A, Mehmetoglu-Gurbuz T, Rocha J, Lakshmanaswamy R. Texas Tech University Health Sciences Center El Paso, El Paso, TX; Texas Tech University Health Sciences Center, El Paso, TX; Graduate School of Biomedical Sciences Texas Tech University Health Sciences Center El Paso, El Paso, TX.
   
  Treatment - Adjuvant Therapy: Adjuvant Chemotherapy
P1-12-01 Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: Final long-term results of the hellenic cooperative oncology group phase III HE10/05 trial
Zagouri F, Koliou G-A, Dimitrakopoulos F, Papadimitriou C, Binas I, Koutras A, Papakostas P, Markopoulos C, Venizelos V, Xepapadakis G, Karanikiotis C, Psyrri A, Bafaloukos D, Kosmidis P, Aravantinos G, Res E, Mauri, D Koumarianou A, Petraki K, Tsipoura A, Pectasides D, Gogas H, Fountzilas G. Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece.
P1-12-02 The tolerance of CREATE-X capecitabine dosing in a United States patient population
Kessler AJ, Berger NS, Huang H-H, Doroshow DB, Klein P. Icahn School of Medicine at Mount Sinai, New York, NY.
P1-12-03 Metaplastic carcinoma of the breast: A single-center 18-year series of 73 cases
Thériault KJ, Ben Moussa M, Perron M, Desbiens C, Poirier B, Poirier É, Leblanc D, Morin C, Lemieux J, Hogue J-C, Boudreau D. CHU de Quebec - Universite Laval, Quebec City, QC, Canada.
P1-12-04 The impact of chemotherapy in elderly early triple negative breast cancer: A population based study from the SEER database
Huang K, Zhang J, Yu Y, Lin Y, Song C. Fujian Medical University Union Hospital, Fuzhou, China.
   
  Treatment - Adjuvant Therapy: Adjuvant Endocrine Therapy
P1-13-01 Withdrawn
P1-13-02 Autophagy inhibition and senolytics to improve the response to fulvestrant + palbociclib in ER positive breast cancer
Finnegan RM. Virginia Commonwealth University, Richmond, VA.
P1-13-03 Radiotherapy vs. endocrine therapy for hormone receptor positive early stage breast cancer accounting for endocrine therapy adherence
Seol SW, Pflederer T, Weller L, Goodman C, Donnelly ED, Hayes JP, Strauss JB. Northwestern University Feinberg School of Medicine, Chicago, IL; University of Illinois at Chicago College of Medicine, Chicago, IL; Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; The University of Texas MD Anderson Cancer Center, Houston, TX.
P1-13-04 Evaluation of the impact Vitamin D and Calcium supplementation on bone mineral density in breast cancer patients using or not taking Aromatase Inhibitors: 5-year follow-up
Antonini M, Salerno GRF, Vieira NDK, Cardoso MS, Solino MD, Vasconcelos RND, Vasconcelos LD, Ferraro O, Mattar A, Lopes1 RGC, Real JM. Hospital Do Servidor Publico Estdual - Francisco Morato Oliveira, Sao Paulo, Brazil; Universidade Mackenzie, Sao Paulo, Brazil; Hospital Perola Byington, Sao Paulo, Brazil.
P1-13-05 Completeness and timeliness of EMR integrated pharmacy dispensing data for early detection of non-adherence to breast cancer adjuvant endocrine therapy
Levy M, Paul S, Lieberenz J. Rush University Medical Center, Chicago, IL.
P1-13-06 The influence of the oncotype DX breast recurrence score on persistence to endocrine therapy in patients with low-risk ER/PR+ invasive breast cancer
Pirruccello J, Kuhn E, Chamberlin M. Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH.
P1-13-07 De-escalation of five-year adjuvant endocrine therapy in patients with ER-low positive breast cancer: propensity-matched analysis from a prospectively maintained cohort
Yu K, Cai Y, Shao Z. Fudan University, Shanghai, China.
P1-13-08 Patterns of adjuvant endocrine therapy, discontinuations, toxicities and quality of life: Development of a model for early discontinuation using the CANTO cohort
Balazard F, Bertaut A, Bordet É, Mulard S, Blanc J, Briot N, Paux G, Dhaini Merimeche A, Rigal O, Coutant C, Fournier M, Jouannaud C, Soulie P, Lerebours F, Cottu P-H, Tredan O, Vanlemmens L, Levy C, Mouret-Reynier M-A, Campone M, Brady KJS, Sasane M, Rice M, Coulouvrat C, Martin A-L, Jacquet A, Vaz-Luis I, Herold C, Pistilli B. Owkin Inc., New York, NY; Centre George François Leclerc, Dijon, France; Sanofi Research and Development, Chilly-Mazarin, France; Sanofi Research and Development, Cambridge, MA; Centre Alexis Vautrin, Vandoeuvre Les Nancy, France; Centre Henri Becquerel, Rouen, France; Institut Bergonié, Bordeaux, France; Institut Jean Godinot, Reims, France; Institut de Cancérologie de L'Ouest – Centre Paul Papin, Anger, France; Institut CURIE - Hôpital René Huguenin, St-Cloud, France; Institut Curie - Site de Paris, Paris, France; Centre Léon Bérard, Lyon, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Centre Jean-Perrin, Clermont-Ferrand, France; Institut de Cancérologie de l’Ouest - Centre René Gauducheau, Nantes Saint Herblain, France; Unicancer, Paris, France; Gustave Roussy, Villejuif, France.
P1-13-09 Withdrawn
   
  Treatment - Adjuvant Therapy: Adjuvant Therapy - Targeted
P1-14-02 Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2- breast cancer (LEADER, part 1)
Spring LM, Scarpetti L, Niemierko A, Isakoff SJ, Moy B, Wander SA, Smith E, Abraham E, Shin J, Patel JM, Comander A, Mulvey T, Bardia A. Massachusetts General Hospital, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA.
P1-14-03 Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple negative breast cancer: A feasibility study
Walsh EM, Gucalp A, Patil S, Edelweiss M, Ross DS, Razavi P, Modi S, Iyengar NM, Sanford R, Troso-Sandoval T, Gorsky M, Bromberg J, Drullinsky P, Lake D, Wong S, DeFusco P, Lamparella N, Gupta R, Tabassum T, Boyle LA, Arumov A, Traina TA. Memorial Sloan Kettering Cancer Center, New York, NY; Hartford HealthCare, Hartford, CT; Lehigh Valley Health Network, Allentown, PA.
P1-14-04 Cardiotoxicity of adjuvant trastuzumab chemotherapy in women with early-stage breast cancer under 50 years of age based on analysis of Japanese insurance claims data
Shimomura A, Ohtsu H, Shimizu C, Sase K. National Center for Global Health and Medicine, Tokyo, Japan; Juntendo University Graduate School of Medicine, Tokyo, Japan.
P1-14-05 The impact of erythropoietin administration concomitantly with adjuvant anti-HER2 treatment on the patients’ outcome: sub-analysis of the ALTTO study
Martins-Branco D, Kassapian M, Debien V, Caparica R, Eiger D, Dafni U, Andriakopoulou C, El-Abed S, Izquierdo M, Vicente M, Chumsri S, Piccart-Gebhart M, Moreno-Aspitia A, Knop AS, Lombard J de Azambuja E. Academic Trials Promoting Team, Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B.), Brussels, Belgium; Frontier Science Foundation-Hellas, Athens, Greece; Novartis Pharma AG, Basel, Switzerland; National and Kapodistrian University of Athens & Frontier Science Foundation-Hellas, Athens, Greece; Breast International Group, Brussels, Belgium; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; Oncology Department, Institut Jules Bordet, Brussels, Belgium; Jacoby Center for Breast Health, Mayo Clinic, Jacksonville, FL; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Calvary Mater Newcastle and Breast Cancer Trials (BCT-ANZ), Newcastle, Australia.
   
  Treatment - Adjuvant: Adjuvant Therapy - Other
P1-15-01 Effect of concomitant statin treatment in postmenopausal patients with hormone-receptor positive early-stage breast cancer receiving adjuvant denosumab or placebo: A post-hoc analysis of ABCSG-18
Minichsdorfer C, Fuereder T, Leutner M, Singer CF, Kacerovsky-Strobl S, Egle D, Greil R, Balic M, Fitzal F, Pfeiler G, Frantal S, Bartsch RA, Gnant M. Internal Medicine I, Vienna, Austria; Medical University of Vienna, Vienna, Austria; Medical University of Innsbruck, Insbruck, Austria; Paracelsus University Salzburg, Salzburg, Austria; Medical University Graz, Graz, Austria; Austrian Breast & Colorectal Cancer Study Group, Vienna, Austria.
P1-15-02 Low incidence of hepatitis B reactivation after chemotherapy in Japanese breast cancer patients with resolved HBV
Fukuda T, Hattori M, Ozaki Y, Inagaki L, Hosonaga M, Fukada I, Kobayashi K, Hara F, Kobayashi T, Yoshio S, Ueno T, Takano T, Ohno S. The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan; Department of Breast Oncology, Aichi Cancer Center, Nagoya, Japan; Department of Liver Diseases, Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Chiba, Japan.
P1-15-03 Assessing the association of statins with clinical outcomes in women with breast cancer
Chongxi R, Jianna S, Lingjun K. Cangzhou Clinical College of Integrated Traditional Chinese and Western Medicine of Hebei Medical University, Cangzhou, China.
P1-15-04 Features of HER2+ metastasic patients (pts) from a prospective registry of advanced breast cancer (ABC), GEICAM/2014-03 (RegistEM)
Álvarez I, Guerrero-Zotano Á, Cruz J, Martínez P, Hernández M, Rodríguez6 CA, Rodríguez-Lescure Á, Antolín S, Adrover E, Andrés R, Falo C, Chacón JI, Miguel A, Servitja S, Galán Gramaje M, Margelí Vila M, Gómez Raposo C, Echarri MJ, Villanueva R, TIbau Martorell A, Varela Ferreiro S, Campo R, Miralles JJ, Bezares S, Rojo F, López-Tarruella S. Unidad de Gestión del Cáncer de Guipúzcoa (Osakidetza-OSI Donostialdea_Onkologikoa)-BioDonostia. GEICAM Spanish Breast Cancer Group, San Sebastián, Spain; Fundación Instituto Valenciano de Oncología (FIVO). GEICAM Spanish Breast Cancer Group, Valencia, Spain; Hospital Universitario de Canarias. GEICAM Spanish Breast Cancer Group, Santa Cruz de Tenerife, Spain; Hospital Universitario Basurto. GEICAM Spanish Breast Cancer Group, Bilbao, Spain; Complejo Hospitalario Universitario de Gran Canaria Doctor Negrín. GEICAM Spanish Breast Cancer Group, Las Palmas de Gran Canaria, Spain; Hospital Universitario de Salamanca-IBSAL. GEICAM Spanish Breast Cancer Group, Salamanca, Spain; Hospital General Universitario de Elche. GEICAM Spanish Breast Cancer Group, Alicante, Spain; Hospital Clínico Universitario Lozano Blesa. GEICAM Spanish Breast Cancer Group, Zaragoza, Spain; Hospital General Universitario de Albacete. GEICAM Spanish Breast Cancer Group, Albacete, Spain; ICO Hospitalet. GEICAM Spanish Breast Cancer Group, Barcelona, Spain; Hospital Virgen de la Salud. GEICAM Spanish Breast Cancer group, Toledo, Spain; ALTHAIA Xarxa asistencial de Manresa. GEICAM Spanish Breast Cancer Group, Barcelona, Spain; Hospital del Mar. GEICAM Spanish Breast Cancer Group, Barcelona, Spain; Hospital Son Llátzer. GEICAM Spanish Breast Cancer Group, Palma de Mallorca, Spain; ICO-Badalona.B-ARGO (Badalona Appllied Reasearch Group in Oncology). GEICAM Spanish Breast Cancer Group, Barcelona, Spain; Hospital Universitario Infanta Sofía. GEICAM Spanish Breast Cancer Group, Madrid, Spain; Hospital Severo Ochoa. GEICAM Spanish Breast Cancer Group, Madrid, Spain; Hospital de Sant Joan Despi Moisés Broggi. GEICAM Spanish Breast Cancer Group, Barcelona, Spain; Hospital de la Santa Creu i Sant Pau. GEICAM Spanish Breast Cancer Group, Barcelona, Spain; Hospital Universitario Lucus Augusti. GEICAM Spanish Breast Cancer Group, Lugo, Spain; GEICAM Spanish Breast Cancer Group, San Sebastián, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain; GEICAM Breast Cancer Group, Madrid, Spain; Hospital Universitario Fundación Jiménez Díaz. Hospital Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Universidad Complutense. GEICAM Spanish Breast Cancer Group, Madrid, Spain; Hospital Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Universidad Complutense. CIBERONC-ISCIII- .GEICAM Spanish Breast Cancer Group, Madrid, Spain.
   
  Treatment - Advanced Disease Treatment: Advanced Chemotherapy
P1-16-01 Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer: A randomized, open-label, multicenter, phase II trial (KCSG-BR15-17)
Lee D-W, Park YH, Jung K-H, Lee K-H, Lee KS, Sohn J, Ahn HK, Jeong JH, Koh S-J, Kim JH, Kim HJ, Lee KE, Kim H-J, Lee KH, Park KH, Lee J, Won HS, Kim T-Y, Im S-A. Seoul National University Hospital, Seoul, Republic of Korea; Samsung Medical Center, Seoul, Republic of Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Yonsei University College of Medicine, Seoul, Republic of Korea; Gachon University Gil Medical Center, Incheon, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Soonchunhyang University Hospital, Cheonan, Republic of Korea; Ewha Womans University Hospital, Seoul, Republic of Korea; Chung-Ang University College of Medicine, Seoul, Republic of Korea; Chungbuk National University Hospital, Cheongju, Republic of Korea; Korea University Anam Hospital, Seoul, Republic of Korea; Seoul St. Mary’s Hospital, Seoul, Republic of Korea; Uijeongbu St. Mary’s Hospital, Uijeongbu, Republic of Korea.
P1-16-02 A randomized phase II study investigating oral metronomic vinorelbine versus conventional dosage of vinorelbine in HER2-negative metastatic breast cancer previously treated with anthracycline or taxane:clinical results and biomarker analysis
Ma F, Liu X, Shi Y, Guan X, Li H, Wang X, Teng Y, Liu Q, Yang J, Li M, Zhang Q, Zhao W, Du C, Sheng L; Xu B. National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; The General Hospital of Ningxia Medical University, Yinchuan, China; State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China; Shandong Cancer Hospital, Jinan, China; Institute of Cancer and Basic Medicine, Chinese Academy of Sciences Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China; The First Hospital of China Medical University, Shenyang, China; Sun Yat-sen Memorial Hospital, Guangzhou, China; First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China; The Second Hospital of Dalian Medical University, Dalian, China; Harbin Medical University Cancer Hospital, Harbin, China; Chinese PLA General Hospital, Beijing, China; Cancer Hospital Chinese Academy of Academy of Medical Sciences, Shenzhen Center, Shenzhen, China; The First Affiliated Hospital of Wannan Medical College, Wuhu, China.
P1-16-03 Response pattern to chemotherapy in metastatic breast cancer (MBC): Real-word data from the Austrian AGMT_MBC-Registry
Rinnerthaler G, Gampenrieder SP, Tinchon C, Petzer Petzer A, Balic M, Sonja H, Zabernigg AF, Egle D, Sandholzer M, Roitner F, Andel J, Pichler P, Hager C, Hubalek M, Knauer M, Singer CF, Greil R. Paracelsus Medical University Salzburg, Salzburg, Austria; LKH Hochsteiermark, Leoben, Austria; Ordensklinikum Linz Barmherzige Schwestern – Elisabethinen, Linz, Austria; Medical University Graz, Graz, Austria; Klinikum Wels-Grieskirchen GmbH, Wels, Austria; County Hospital Kufstein, Kufstein, Austria; Medical University Innsbruck, Innsbruck, Austria; Academic Teaching Hospital Feldkirch, Feldkirch Salzburg, Austria; Hospital Braunau, Braunau, Austria; Landeskrankenhaus Steyr, Steyr, Austria; University Hospital St.Pölten, St.Pölten, Austria; Breast Center Dornbirn, Dornbirn, Austria; Breast Health Center Schwaz, Schwaz, Austria; Breast Center Eastern Switzerland, St. Gallen, Switzerland; Medical University of Vienna, Vienna, Austria.
P1-16-04 Capecitabine efficacy after progression on endocrine treatment and cycline-dependant-kinase 4/6 inhibitor combination in metastatic hormone-receptor positive breast cancer
Bender L, Pflumio C, Trensz P, Pierard L, Kalish M, Fischbach C, Petit T. Institut de Cancérologie Strasbourg - Europe, Strasbourg, France.
P1-16-05 Oraxol + Encequidar (OPac+E) vs IV paclitaxel (IVPac) in the treatment of patients with metastatic breast cancer (mBC) (Study KX-ORAX-001): Subgroup survival analysis of patients with hepatic dysfunction
Umanzor G, Rugo HS, Barrios FJ, Vasallo RH, Chivalan MA, Bejarano S, Ramirez JR, Fein L, Kowalyszyn RD, Cutler DL, Kramer D, Wang H, Kwan RMF. Liga Contra el Cancer, San Pedro Sula, Honduras; UCSF Hellen Diller Family Comprehensive Cancer Center, San Francisco, CA; Instituta Cancerologica de Cancerologica (ICAN), Guatemala City, Guatemala; Clinical Research RD, Santo Domingo, Dominican Republic; CLEAN Clinical Medica, Guatemala City, Guatemala; Excel Medica, San Pedro Sula, Honduras; CRESEM, Quetzaltenango, Guatemala; Instituto de Oncologia de Rosario, Rosario, Argentina; Centro de Investigaciones Clínica,, Clinica Veidma, Argentina; Athenex, Buffalo, NY.
P1-16-06 In real world, a high percentage of premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer receive chemotherapy as first-line treatment: A study of the National Cancer Center, China
Li Y, Mo H, Guan X, Lin S, Wang Z, Chen Y, Chen S, Li Q, Cai R, Wang J, Luo Y, Fan Y, Yuan P, Zhang P, Li Q, Ma F, Xu B. National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
P1-16-07 A synthetic lethality treatment strategy for p53 mutant breast cancer
Bakin A, Zonneville J, Wang M, Alruwaili M, Eng1 K Iyer R, Park B, Fountzilas C. Roswell Park Comprehensive Cancer Center, Buffalo, NY; Vanderbilt University Medical Center, Nashville, TN.
   
  Treatment - Advanced Disease Treatment: Advanced Endocrine Therapy
P1-17-01 Response of persistent metastatic ER+/Her2- breast cancer treated with fulvestrant plus enzalutamide
Richer J, Spoelstra N, Winchester A, Wulfkuhlue J, Gallagher R, Sams S, Vidal G, Kabos P, Diamond J, Shagisultanova E, Afghahi A, Mayordomo J, McSpadded T, Crawford G, Borges V, Gao D, Petricoin E, Elias A. University of Colorado Anschutz Medical Campus, Aurora, CO; 5. Center for Applied Proteomics and Molecular Medicine, George Mason University, Washington DC, DC; George Mason University, Washington DC, DC; West Cancer Center and Research Institute and University of Tennessee Health Science Center, Germantown, TN.
P1-17-02 ZN-c5, an oral selective estrogen receptor degrader (SERD), in women with advanced estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer
Kalinksy K, Abramson V, Chalasani P, Linden HM, Alidzanovic J, Layman RM, Vranješ Ž, Nangia JR, Crew KD, Andric Z, Milovic-Kovacevic M, Trifunovic J, Suarez J, Suster M, Ptaszynski M, Mortimer J. Columbia University Medical Center, New York, NY; Vanderbilt Medical Center, Nashville, TN; University of Arizona Cancer Center, Tucson, AZ; University of Washington, Seattle, WA; University Clinical Centre Tuzla, Tuzla, Bosnia and Herzegovina; MD Anderson Cancer Center, Houston, TX; University Clinical Centre of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina; Baylor College of Medicine, Houston, TX; Clinical Hospital Centre Bezanijska Kosa, Belgrade, Serbia; Institute for Oncology and Radiology of Serbia, Belgrade, Serbia; Oncology Institute of Vojvodina, Sremska Kamenica, Serbia; Zentalis Pharmaceuticals, New York, NY; City of Hope, Duarte, CA.
P1-17-03 H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer, phase 1b study
Johnston S, Pluard TJ, Wang JS, Hamilton EP, Juric D, Scholz CR, Hnitecki E, Dar S, Gao L, Cantagallo L, Korpal M, Xiao JA, Yu L, Sahmoud T, Gualberto A. Royal Marsden NHS FDN Trust, London, United Kingdom; St Luke's Cancer Institute, Kansas City, MO; Sarah Cannon Research Institute, Florida Cancer Specialists, Sarasota, FL; Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Massachusetts General Hospital, Boston, MA; H3 Biomedicine Inc., Cambridge, MA; Eisai Inc., Cambridge, MA.
P1-17-04 Hormone therapy (HT) brings more survival benefits than capecitabine (CAP) as maintenance therapy following the 1st-line chemotherapy in HR+/HER2-ABC/MBC: Update primary endpoint of OVERSTEP(ZJCHBC001)
Wang X-J, Huang J, Shao X-y, Cai L, Yin Y-m, Zhang L-l, Shen P, Shi Y-x. Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China; Cancer Hospital Affiliated to Harbin Medical University, Harbin, China; Jiangsu Province Hospital, Nanjing, China; Jiangsu Cancer Hospital, Nanjing, China; The First Affiliated Hospital of Zhejiang University, Hangzhou, China; Sun Yat-sen University Cancer Center, Guangzhou, China.
P1-17-05 Benefit of endocrine therapy for metastatic breast cancer after loss of hormone receptor expression in patients with HR+/HER2- primary tumors
File D, Abdou Y, Wheless A, Dees C, Carey L. University of North Carolina, Chapel Hill, NC.
P1-17-06 Impact of body mass index on the efficacy of aromatase inhibitors in patients with metastatic breast cancer
Patel R, Li Z, Zimmerman BS, Fink MY, Wells JD, Zhou X, Ayers KL, Redfern A, Newman S, Chen R, Oh WK, Tiersten A. Icahn School of Medicine at Mount Sinai, New York, NY; Sema4, Stamford, CT.
P1-17-07 Consequences of stopping a 4/6 cyclin D-dependent kinase Inhibitor in metastatic breast cancer patients with clinical benefit on endocrine treatment, in the context of the COVID-19 outbreak
Martin S, Pflumio C, Trensz P, Schaff-Wendling F, Kalish M, Fischbach C, Pierard L, Limacher J-M, Velten M, Petit T. Institut de Cancérologie Strasbourg - Europe, Strasbourg, France; Clinique de l'Orangerie, Strasbourg, France; Hôpital Pasteur, Colmar, France.
P1-17-08 Abemaciclib and endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: A real-world UK multicentre experience
Battisti NML, Morrison L, Nash T, Senthivel N, Kestenbaum S, Begum P, Obeid M, Hayhurst W, Yang D, Gafoor S, Brown C, Rehman F, Kenny L, Hatcher O, Susan S, Williams J, Brown A, Rozati H, Alexandros A, Sawyer E, Gousis C, Karapanagiotou E, Rigg A, Rapti K, Roylance R, Beresford M, Gee AL, Konstantis A, King J, Nathan M, Spurrell E, Pearce M, Bradwell D, Denton A, Swain K, McGrath S, Allen M, Ring A, Johnston S, Raja F. The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Royal Free Hospital NHS Foundation Trust, London, United Kingdom; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Imperial College Healthcare NHS Trust, London, United Kingdom; North Middlesex University Hospital NHS Trust, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Royal United Hospital, Bath, United Kingdom; Princess Alexandra Hospital NHS Trust, Harlow, United Kingdom; King's College Hospital NHS Foundation Trust, London, United Kingdom; Whittington Health, London, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; Macclesfield District General Hospital, Macclesfield, United Kingdom; Mount Vernon Cancer Centre, Northwood, United Kingdom; Hull University Teaching Hospital NHS Trust, Hull, United Kingdom.
P1-17-09 Efficacy of limited dose modifications for palbociclib-related grade 3 neutropenia in hormone receptor positive metastatic breast cancer
Kim S-G, Kim MH, Park S, Kim GM, Kim JH, Kim JY, Park HS, Park S, Park BW, Kim SI, Ji JH, Jeong J, Shin K, Lee J, Kim H-D, Jung KH, Sohn J. Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Department of Biostatistics and Computing, Yonsei University College of Medicine, Seoul, Republic of Korea; Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea; Division of Breast Surgery, Department of Surgery, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Division of Breast Surgery, Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea; Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
P1-17-10 H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer - A phase II study
Hamilton EP, Wang JS, Pluard T, Morikawa A, E Dees C, Jones RH, Haley B, Armstrong A, Cohen AL, Munster P, Wright GS, Kayali F, Cantagallo L, Korpal M, Long J, Xiao J, Destenaves B, Gao L, Sahmoud T, Gualberto A, Juric D. Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL; Saint Luke's Cancer Institute, Kansas City, MO; University of Michigan, Ann Arbor, MI; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; Cardiff University and Velindre Cancer Centre, Cardiff, United Kingdom; University of Texas Southwestern Medical Center, Dallas, TX; The Christie Hospital, Manchester, United Kingdom; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; University of California San Francisco, San Francisco, CA; Sarah Cannon Research Institute, Florida Cancer Specialists North, Saint Petersburg, FL; H3 Biomedicine Inc., Cambridge, MA; H3 Biomedicine, Cambridge, MA; Eisai Inc., Cambridge, MA; Massachusetts General Hospital, Boston, MA.
P1-17-11 Updated data from AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), combined with palbociclib in postmenopausal women with ER+/HER2- advanced breast cancer
Chandarlapaty S, Linden HM, Neven P, Petrakova K, Bardia A, Kabos P, Braga S, Boni V, Gosselin A, Celanovic M, Cohen P, Paux G, Pelekanou V, Ternès N, Lee JS, Campone M. Memorial Sloan Kettering Cancer Center, New York, NY; University of Washington Medical Center, Seattle Cancer Care Alliance, Seattle, WA; Universitair Ziekenhuis Leuven, Leuven, Belgium; Masarykuv Onkologický Ustav, Brno, Czech Republic; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; University of Colorado Denver, Aurora, CO;; Instituto CUF de Oncologia, Lisbon, Portugal; START Madrid-Centro, Madrid, Spain; Sanofi, Paris, France; Sanofi, Cambridge, MA; Institut de Cancérologie de l'Ouest, René Gauducheau, St Herblain, France.
P1-17-12 Preliminary data from a phase I/II, multicenter, dose escalation study of OP-1250, an oral CERAN/SERD, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer
Patel M, Alemany C, Mitri Z, Makower D, Borges V, Sparano J, Le T, Klein P, Lawrence J, Kushner P, Faltaos D, Harmon C, Myles D, Zujewski J, Hamilton E. Florida Cancer Specialists, Sarasota, FL; AdventHealth, Orlando, FL; Knight Cancer Institute OHSU, Portland, OR; Montefiore Medical Center, New York, NY; University of Colorado, Denver, CO; Mount Sinai Health System, New York, NY; Olema Oncology, San Francisco, CA; Olema Oncology, Chapel Hill, NC; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.
   
  Treatment - Advanced Disease Treatment: Advanced Therapy - Targeted
P1-18-01 Withdrawn
P1-18-02 Withdrawn
P1-18-03 Alpelisib + fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + aromatase inhibitor (AI): 18-month follow-up of BYLieve Cohort A
Ciruelos EM, Lerebours F, Rugo HS, Ruiz-Borrego M, Drullinsky P, Prat A, Bachelot T, Neven P, Park YH, Turner N, Juric D, Gu E, Arce CH, Akdere M, Chia S. Hospital Universitario 12 de Octubre, Madrid, Spain; Institut Curie, Saint-Cloud, France; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Hospital Virgen del Rocío de Sevilla, Seville, Spain; Memorial Sloan Kettering Cancer Center, New York, NY; Hospital Clinic of Barcelona, Barcelona, Spain; Centre Léon Bérard, Lyon, France; University Hospitals, Leuven, Belgium; Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea; The Royal Marsden and Institute of Cancer Research, London, United Kingdom; Massachusetts General Hospital Cancer Center, Boston, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada.
P1-18-04 Feasibility of palbociclib in women aged 70 and older with resistant and/or pretreated advanced breast cancer in the PALOMAGE study
Brain E, Pulido M, Paillaud E, Grosjean J, Mina W, Caillet P, Tassy L, Soubeyran P, Bouteiller F, Rifi N, Vauthier J-M, Falandry C, Carola E. Institut Curie, Saint-Cloud & Paris, France; PACAN Platform, CLCC Bergonié, Bordeaux, France; AP-HP, Paris Cancer Institute CARPEM, Hôpital Europeen Georges Pompidou, Department of Geriatrics, Paris, France; Clinique des Dentellières, Valenciennes, France; Centre Hospitalier de Troyes, Troyes, France; Institut Paoli-Calmette, Marseille, France; CLCC Bergonié, Bordeaux, France; Pfizer, Paris, France; CH Lyon Sud, Lyon, France; CH GHPSO, Senlis, France.
P1-18-05 Early changes in circulating tumor DNA and its effect on clinical outcomes in patients with advanced breast cancer receiving the CDK4/6 inhibitor palbociclib: Genotyping results from POLARIS
Tripathy D, Zhang Z, Blum JL, Karuturi MS, McCune SL, Telivala B, Lakhanpal S, Patel K, Frank RC, Lu K, Deshpande C, Wang Y, Liu Y, Bardia A. The University of Texas MD Anderson Cancer Center, Houston, TX;Pfizer Inc, San Diego, CA;Texas Oncology, Baylor-Sammons Cancer Center, US Oncology, Dallas, TX;Wellstar Health System, Marietta, GA;Cancer Specialists of North Florida, Jacksonville, FL;Saint Vincent’s Birmingham, Birmingham, AL;CARTI Cancer Center, Little Rock, AR;Whittingham Cancer Center at Norwalk Hospital, Norwalk, CT;UPMC Hillman Cancer Center Pinnacle, Harrisburg, PA;Pfizer Inc, New York, NY;Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
P1-18-06 Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2- positive metastatic breast cancer, followed by T-DM1 after progression
Wildiers H, Marreaud S, Dal Lago L, Vuylsteke P, Curigliano G, Waters S, Brouwers B, Meulemans B, Sousa B, Poncet C, Brain E. University Hospitals Leuven, Leuven, Belgium; EORTC, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; CHU UCL Namur Sainte Elisabeth, Namur, Belgium; Istituto Europeo di Oncologia, IRCCS,, Milano, Italy; Velindre NHS Trust- Velindre Cancer Centre, Cardiff, United Kingdom; AZ Sint-Jan Hospital, Brugge, Belgium; Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal; Institut Curie - Hôpital René Huguenin, Saint-Cloud, Paris, France.
P1-18-07 Impact of PIK3CA mutation (PIK3CA-mt) clonality on alpelisib (ALP) activity based on real-world evidence (RWE) following liquid biopsy testing
Juric D, Weipert C, Bucheit L, Nagy R, Odegaard J, Yu J, Zhang N, Liao J. Massachusetts General Hospital, Boston, MA; Guardant Health, Redwood City, CA.
P1-18-08 Effect of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy (≤6 mo or >6 mo) on alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve
Chia S, Ciruelos EM, Rugo HS, Lerebours F, Ruiz-Borrego M, Drullinsky P, Prat A, Bachelot T, Turner N, Gu E, Arce C, Akdere M, Juric D. British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Hospital Universitario 12 de Octubre, Madrid, Spain; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Institut Curie, Saint-Cloud, France; Hospital Virgen del Rocío de Sevilla, Seville, Spain; Memorial Sloan Kettering Cancer Center, New York, NY; Hospital Clinic of Barcelona, Barcelona, Spain; Centre Léon Bérard, Lyon, France; The Royal Marsden and Institute of Cancer Research, London, United Kingdom; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Massachusetts General Hospital Cancer Center, Boston, MA.
P1-18-09 Impact of prior adjuvant trastuzumab (aT) on clinical characteristics, patterns of recurrence and outcomes in 4145 patients with Her2 positive (HER2+) metastatic breast cancer (MBC)- Results from the French ESME UNICANCER program
Le Du F, Carton M, Saghatchian M, Perol D, Pistilli B, Brain E, Loirat D, Vanlemmens L, Vermeulin T, Levy C, Goncalves A, Ung M, Robert M, Jaffre A, Robain M, Delaloge S, Dieras V. CRLCC Eugène Marquis, Rennes, France; Institut Curie, Paris, France; American Hospital of Paris, Neuilly Sur Seine, France; Department of Biostatistics, DRCI, Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; CLCC Rene Huguenin Institut Curie, Saint Cloud, France; Département d’Oncologie Médicale, Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France; Centre Henri-Becquerel, Rouen, France; Centre Francois Baclesse, Caen, France; Institut Paoli-Calmettes, Marseille, France; UNGInstitut Claudius Regaud, IUCT-Oncopole, Toulouse, France; Institut de Cancérologie de l'Ouest - René Gauducheau, Saint Herblain, France; Institut Bergonié, Bordeaux, France; Unicancer, Paris, France.
P1-18-10 A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)
Howell SJ, Kenny LM, Simon Lord, Matthew G Krebs, Tobias Arkenau, Richard Baird, Iain R MacPherson, Ash Bahl, Glen Clack, Edward Ainscow, Anthony GM Barrett, Paul A Dickinson, Matthew J Fuchter, Manfred Lehnert, Simak Ali, Stuart McIntosh and Charles Coombes. The University of Manchester, Manchester, United Kingdom Imperial College, London, United Kingdom Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom HCA Healthcare, London, United Kingdom Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom University of Glasgow, Glasgow, United Kingdom Carrick Therapeutics, Dublin, Ireland SEDA Pharmaceutical Development Services, Stockport, United Kingdom Carrick Therapeutics, Dublin, United Kingdom.
P1-18-11 Analysis of first-line (1L) patients (pts) with de novo disease vs late relapse and all pts with vs without prior chemotherapy (CT) in the MONALEESA-3 (ML-3) trial
De Laurentiis M, Lambertini M, Chia S, Rugo HS, Petrakova K, Villanueva , Hurvitz S, J. Beck T, Lteif A, Haftchenary S, Deore U, Wu J, El-Saghir N. Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, Italy; Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy; BC Cancer, Vancouver, BC, Canada; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Masaryk Memorial Cancer Institute, Brno, Czech Republic; University Hospital of Besançon, Jean-Minjoz University Hospital, Besançon, France; University of California, Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA; Highlands Oncology Group, Fayetteville, AR; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharmaceuticals Canada, Montreal, QC, Canada; American University of Beirut Medical Center, Beirut, Lebanon.
P1-18-12 Moved to General Session 3
P1-18-13 Efficacy and safety of palbociclib plus endocrine therapy in Black and Hispanic patients with hormone receptor positive/human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2- ABC) participating in the PALOMA trials
Isaacs C, Mahtani R, Lynce F, Sleckman B, Castrellon A, Kalmadi S, Theall KP, Huang X, Bananis E, Rugo HS. Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC; Sylvester Cancer Center, University of Miami, Deerfield Beach, FL; Dana-Farber Cancer Institute, Harvard School of Medicine, Boston, MA; Mercy Hospital St. Louis, St. Louis, MO; Breast Cancer Center, Memorial Healthcare System, Hollywood, FL; Ironwood Cancer and Research Centers, Chandler, AZ; Pfizer Inc, Cambridge, MA; Pfizer Inc, La Jolla, CA; Pfizer Inc, New York, NY; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
P1-18-14 Alpelisib monotherapy for PI3K-altered, pre-treated advanced breast cancer: A phase II study
Savas P, Lo LL, Luen SJ, Blackley EF, van Geelen CT, Ko Y-A, Moodie K, Callahan JW, Weng C-F, Zivanovic Bujak A, Yeung MM, Sarah Ftouni1, Francis PA, Dawson S-J, Loi S. Division of Research, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia; Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia.
P1-18-15 Real-world efficacy of ribociclib + aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) locally advanced or metastatic breast cancer: Fourth interim analysis from the RIBANNA study
Lüftner D, Brucker C, Decker T, Fasching P, Göhler T, Jackisch C, Janssen J, Köhler A, Lüdtke-Heckenkamp K, van Mackelenbergh M, Marmé F, Nusch A, Rautenberg B, Reimer T, Schmidt M, Weide R, Wimberger P, Nabieva N, Roos C, Wöckel A. Department of Hematology, Oncology and Tumor Immunology, Charité University Hospital, Berlin, Germany; Klinikum Nürnberg Nord, Paracelsus Medical University, Nürnberg, Germany; Oncology Ravensburg, Ravensburg, Germany; Department of Obstetrics and Gynecology, University Hospital Erlangen, Erlangen, Germany; Onkozentrum Dresden/ Freiberg, Dresden, Germany; Department of Obstetrics and Gynecology, Sana Klinikum Offenbach, Offenbach, Germany; Medizinische Studiengesellschaft Nord-West GmbH, Westerstede, Germany; Gemeinschaftspraxis Drs. Köhler, Fuchs, Langen, Germany; Department of Oncology and Hematology, Niels-Stensen-Kliniken, Georgsmarienhütte, Germany; Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Med. Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany; Practice for Hematology and Medical Oncology Velbert, Velbert, Germany; Universitätsklinikum Freiburg, Freiburg, Germany; University Hospital Rostock, Rostock, Germany; Universität Mainz, Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Mainz, Germany; InVO GbR, Koblenz, Germany; Universitätsklinikum Carl Gustav Carus, Technische Universität, Dresden, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Department of Obstetrics and Gynecology, University Hospital Würzburg, Würzburg, Germany.
P1-18-16 First line aromatase inhibitor (AI) + palbociclib with randomized switch to fulvestrant + palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: global safety results of PADA-1, a UCBG-GINECO phase III trial
Delaloge S, Hardy-Bessard A-C, Bachelot T, Pierga J-Y, Canon J-L, Clatot F, André F, De La Motte Rouge T, Pistilli B, Dalenc F, Dohollou N, Arsene O, Petit T, Riedl C, Morvan F, Marti A, Lachaier E, Achille M, Gozy M, Escande A, Mille D, Trouboul F, Marques S, Lemonnier J, Berger F, Bidard F-C. Gustave Roussy, Villejuif, France; Cario, Plérin, France; Centre Leon Berard, Lyon, France; Curie Institute, Paris, France; Hopital de Charleroi, Charleroi, France; Centre Henri Becquerel, Rouen, France; Centre Eugene Marquis, Rennes, France; Oncopole Toulouse IUCT, Toulouse, France; Polyclinique Bordeaux Nord, Bordeaux, France; CH Blois, Blois, France; Centre Paul Strauss, Strasbourg, France; CH Mont de Marsan, Mont de Marsan, France; CH Pontoise, Pontoise, France; CH Auxerre, Auxerre, France; CH Amiens, Amiens, France; Clinique de l'orangerie, Strasbourg, France; Clinique de l'Europe, Amiens, France; Clinique Sainte Anne, Strasbourg, France; Medipole de savoie, Challes les Eaux, France; CH Bretagne Atlantique, Vannes, France; Unicancer, Paris, France.
P1-18-17 Phase I study of cfi-402257, an oral ttk inhibitor, in patients with advanced solid tumors with breast cancer expansion cohorts
Hilton J, Renouf DJ, Cescon DW, Hansen AR, Razak ARA, Stayner L-A, Denny T, Fletcher G, Mak TW, Bray M, Bedard PL. Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; BC Cancer Agency, Vancouver, BC, Canada; Princess Margaret Cancer Centre, Toronto, ON, Canada; Treadwell Therapeutics, Toronto, ON, Canada.
P1-18-18 Real-world natural history data among patients with PIK3CA-mutant and PIK3CA-wild-type advanced breast cancer
Razavi P, Parikh RC, Acevedo B, Hitchens A, Ahmed M, Safonov A, Ferraro E, Jhaveri K, Sidel M, Simmons S, Robson M, Chandarlapaty S, Balu S. Memorial Sloan Kettering Cancer Center, New York, NY; RTI-Health Solutions, Research Triangle Park, NC; Novartis Pharmaceuticals Corporation, East Hanover, NJ.
P1-18-19 Long term results with everolimus in advanced hormone receptor positive breast cancer in a multicenter national real world observational study (ESME)
Francois-Martin H, Lardy-Cleaud A, Pistilli B, Levy C, Diéras V, Frenel J-S, Guiu S, Mouret-Reynier M-A, Mailliez A, Eymard J-C, Petit T, Ung M, Desmoulins I, Augereau P, Bachelot T, Uwer L, Debled M, Ferrero J-M, Veyret C, Goncalves A, Chevrot M, Cottu PH. Institut Curie, Paris, France; Centre Leon Berard, Lyon, France; Gustave Roussy, Villejuif, France; centre Francois Baclesse, Caen, France; Centre Eugène Marquis, Rennes, France; Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Institut de Cancérologie de la Méditerranée, Montpellier, France; Centre Jean Perrin, Clermont Ferrand, France; Institut Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; IUCT - Oncopole, Toulouse, France; Centre Georges Francois Leclerc, Dijon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Bergonié, Bordeaux, France; Centre Antoine Lacassagne, Nice, France; Centre Henri Becquerel, Rouen, France; Institut Paoli Calmettes, Marseille, France; Direction des Data, Unicancer, Paris, France.
P1-18-20 Real-world effectiveness of palbociclib plus letrozole vs letrozole alone for metastatic breast cancer with lung/liver metastases: Flatiron database analysis
Brufsky A, Liu X, Li B, McRoy L Layman RM. Comprehensive Breast Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA; Pfizer Inc, New York, NY; The University of Texas MD Anderson, Houston, TX.
P1-18-21 Abemaciclib plus fulvestrant or nonsteroidal aromatase inhibitor in participants with HR+, HER2- breast cancer - A pooled analysis of the endocrine therapy-naïve participants with measurable disease in MONARCH 2 and MONARCH 3
Goetz MP, Gonzalez Trujillo JL, Toi M, Huober J, Llombart-Cussac A, Zhang W, Knoderer H, Haddad N, Van Hal G, Sledge, Jr. GW. Mayo Institute, Rochester, MN; Fundacion Rodolfo Padilla AC, Leon Guanajuato, Mexico; Kyoto University, Kyoto, Japan; University of Ulm, Ulm, Germany; Hospital Arnau Villanova, Valencia, Spain; Eli Lilly and Company, Indianapolis, IN; Stanford University, Stanford, CA.
P1-18-22 AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation
Wander SA, Micalizzi DS, Dubash T, Juric D, Spring LM, Vidula N, Keenan J, Beeler M, Viscosi E, Che D, Fisher EL, Hepp RA, Moy B,Isakoff SJ, Ellisen LW, Supko JG, Maheswaran S, Haber DA, Bardia A. Massachusetts General Hospital Cancer Center, Boston, MA.
P1-18-23 Implementation and evaluation of a shared care model between oncologists and pharmacists for advanced breast cancer patients on cyclin-dependent kinase (CDK) 4/6 inhibitors
Chan A, Labelle S, Goh E. BC Cancer, Surrey, BC, Canada.
P1-18-25 Real-world quality of life (QoL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC) treated with palbociclib: A patient-reported outcome (PRO) analysis from POLARIS
Karuturi MS, Rocque GB, Cappelleri JC, Blum JL, McCune SL, Telivala B, Kurian S, Anderson DM, Tsai M, Pluard T, Migas J, Wang Y, Montelongo MZ, Tripathy D. The University of Texas MD Anderson Cancer Center, Dallas, TX; The University of Alabama at Birmingham, Birmingham, AL; Pfizer Inc, Groton, CT; Texas Oncology, Baylor-Sammons Cancer Center, US Oncology, Dallas, TX; Wellstar Health System, Marietta, GA; Cancer Specialists of North Florida, Jacksonville, FL; West Virginia University, Morgantown, WV; Health Partners Institute, St. Paul, MN; Minnesota Oncology, Minneapolis, MN; Saint Luke’s Cancer Institute, Kansas City, MO; Mid-Illinois Hematology & Oncology Associates, Ltd., Normal, IL; Pfizer Inc, New York, NY; ICON plc, North Wales, PA; The University of Texas MD Anderson Cancer Center, Houston, TX.
P1-18-26 Intracranial efficacy of tucatinib, palbociclib and letrozole combination in patients with HR+/HER2+ breast cancer and brain metastases
Shagisultanova E, Gradishar W, Brown-Glaberman U, Chalasani P, Brenner A, Stopeck A, Mayordomo J, Diamond J, Kabos P, Borges VF. University of Colorado Denver, Aurora, CO; Northwestern University, Chicago, IL; University of New Mexico, Albuquerque, NM; University of Arizona, Tuscon, AZ; University of Texas Health San Antonio, San Antonio, TX; Stony Brook University, New York, NY.
P1-18-28 Phase IV study evaluating effectiveness and safety of talazoparib in patients with locally advanced or metastatic HER2 negative breast cancer and a BRCA1 or BRCA2 mutation (ViTAL)
Loirat D, Duboys de Labarre M, Essner C, Hrab I, Thery J-C, Jouannaud C, Villanueva C, Vuagnat P, Soibinet-Oudot P, Creisson A, Mailliez A, Mouysset J-L, Salabert L, Dohollou N, Fumet J-D, De La Motte Rouge T, Vauthier J-M, Decrop M, Pujol P. Institut Curie, Paris, France; Institut Régional du Cancer Montpellier, Montpellier, France; Hôpital Pasteur, Colmar, France; Centre François Baclesse, Caen, France; Centre Henri Becquerel, Rouen, France; Institut Jean Godinot, Reims, France; Clinique Clementville, Montpellier, France; Institut Godinot, Reims, France; Centre Antoine-Lacassagne, Nice, France; Centre Oscar Lambret, Lille, France; Hôpital Privé de Provence, Aix en Provence, France; Institut Bergonié, Bordeaux, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Centre Georges François Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Pfizer SAS, Paris, France; CHU Montpellier, Montpellier, France.
P1-18-29 Male patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) receiving palbociclib in the real world: patient characteristics, treatment patterns, and outcomes from the POLARIS study
Blum J, DiCristo C, Gordon D, Karuturi M, Oubre D, Jepsen E, Cuevas J, Lakhanpal S, Zhang Z, Wang Y, Tripathy D. Texas Oncology, Baylor-Sammons Cancer Center, US Oncology, Dallas, TX; Pfizer Inc, New York, NY; Munson Medical Center, Traverse City, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; Pontchartrain Cancer Center, Hammond, LA; Novant Health, Winston-Salem, NC; St. Louis Cancer Care, Bridgeton, MO; Saint Vincent’s Birmingham, Birmingham, AL; Pfizer Inc, San Diego, CA.
P1-18-31 Accessibility of CDK4/6 inhibitors for breast cancer patients in the Netherlands
Luyendijk M, Blommestein H, Jager A, Siesling S, Uyl-de Groot C. IKNL, Utrecht, Netherlands; ESHPM, Rotterdam, Netherlands; Erasmus MC Cancer Institute, Rotterdam, Netherlands.
P1-18-32 A nationwide real-world study for evaluation of efficacy and safety of T-DM1 in patients with HER2-positive locally-advanced unresectable or metastatic breast cancer in Korea (KCSG BR19-15)
Baek SK, Jeong J-H, Park Y-H, Ahn HK, Kim MH, Park IH, Suh YJ, Lee D-W, Sim SH, Kim JH, Shim H-J, Chae Y, Koh S-J, Lee H, Lee J, Byun J-H, Seol Y, Lee EM, Ahn JS, Jung K-H, Im S-A, Lee KS, Sohn J, Lee KE. Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, Republic of Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Gachon University Gil Medical Center, Incheon, Republic of Korea; Yonsei University College of Medicine, Seoul, Republic of Korea; Korea University Guro Hospital, Seoul, Republic of Korea; Inha University College of Medicine, Incheon, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Goyang, Republic of Korea; Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea; Chonnam National University Medical School and Hwasun Hospital, Gwangju, Republic of Korea; Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea; Ulsan University Hospital, Ulsan, Republic of Korea; Korea Cancer Center Hospital, Seoul, Republic of Korea; Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea; Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Incheon, Republic of Korea; Pusan National University Hospital, Busan, Republic of Korea; Kosin University Gaspel Hospital, Busan, Republic of Korea; Ewha Womans University Hospital, Seoul, Republic of Korea.
P1-18-33 Real-world outcomes with palbociclib, abemaciclib and ribociclib; experience of a tertiary oncology centre in the United Kingdom
Wang L, Ibrahim M, Anthony Neal A. Royal Surrey County Hospital, Guildford, United Kingdom.
P1-18-34 Solti-1507 IPATHER - A phase Ib study of ipatasertib (IPAT) and dual anti-HER2 therapy with pertuzumab and trastuzumab (HP) in patients with HER2-positive (HER2+) advanced breast cancer (ABC) and a PIK3CA mutation (mut): Results from the first safety cohort
Oliveira M, Ciruelos E, Morales S, Gavilá J, Quiroga V, Vega E, Bofill JS, Cortegoso A, Henao F, Tolosa P, Canes J, Villagrasa P, Gonzalez Farré X, Pascual T, Saura C. Medical Oncology Department, Vall d’Hebron University Hospital, and Breast Cancer and Melanoma Group, Vall d’Hebron Institute of Oncology (VHIO) / SOLTI Breast Cancer Research Group, Barcelona, Spain; Medical Oncology Dept, University Hospital 12 De Octubre / SOLTI Breast Cancer Research Group, Madrid / Barcelona, Spain; Medical Oncology, Hospital Universitario Arnau de Vilanova, Lleida, Spain; Department of Medical Oncology, Instituto Valenciano de Oncología / SOLTI Breast Cancer Research Group, Valencia / Barcelona, Spain; Medical Oncology, Badalona-Applied Research Group in Oncology (B-ARGO Group), Catalan Institute of Oncology, Barcelona, Spain; Medical Oncology, Centro Integral Oncológico Clara Campal, Madrid, Spain; Medical Oncology, Hospital Virgen del Rocío, Sevilla, Spain; Servicio Oncología Médica, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain; Medical Oncology, Hospital Virgen de Macarena, Sevilla, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Medical Oncology, Institut Oncològic Dr. Rosell / SOLTI Breast Cancer Research Group, Barcelona, Spain.
P1-18-35 Futibatinib in combination with fulvestrant in patients with metastatic breast cancer (MBC) harboring high-level FGFR1 amplification: Preliminary data from a phase 2 study
Damodaran S, Unni N, Giridhar KV, Daniel B, Howell S, Costa L, Ferreira M, Shimura M, Tomlinson G, Gil M, Turner N. MD Anderson Cancer Center, Houston, TX; University of Texas Southwestern Medical Center, Dallas, TX; Mayo Clinic, Rochester, MN; Tennessee Oncology, Chattanooga, TN; The Christie NHS Foundation Trust, Manchester, United Kingdom; Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal; Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal; Taiho Pharmaceutical Co., Ltd., Tokyo, Japan; Taiho Pharma Canada, Inc., Oakville, ON, Canada; Taiho Oncology, Inc., Princeton, NJ; Royal Marsden Hospital, London, United Kingdom.
P1-18-36 Withdrawn
P1-18-37 Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 and 6i for HR+, HER2- MBC in the real world
Kalinsky KM, Kruse M, Nash Smyth E, Guimaraes CM, Gautam S, Nisbett AR, Fisher MD, Cui ZL, Bowman L. Winship Cancer Institute of Emory University, Atlanta, GA; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Eli Lilly and Company, Indianapolis, IN; ConcertAI, Memphis, TN.
P1-18-38 Moved to Spotlight Session 8
   
  Treatment - Advanced Disease Treatment: Advanced Therapy - Other
P1-19-01 Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone - A large institutional study
Singareeka Raghavendra A, Ha MJ, Kettner NM, Damodaran S, Layman R, Hunt KK, Shen Y, Tripathy D, Keyomarsi K. The University of Texas MD Anderson Cancer Center, Houston, TX.
P1-19-02 Repurposing the FOXO4 senolytic against triple-negative breast cancer
Putavet D, Baar M, Shi T, Lehmann J, Leyten T, Bouma E, Khalil A, Vos H-J, Burgering B, Dansen T, Derksen P, de Keizer P. University Medical Center Utrecht, Utrecht, Netherlands.
P1-19-03 Phase II trial of durvalumab and tremelimumab in the hormone receptor-positive metastatic breast cancer with high tumor mutational burden selected by whole exome sequencing: Korean cancer study group trial (KCSG BR17-04)
Moon YW, Kim E, Kim MH, Kim GM, Kim S-G, Chae Y, Lee J, Jeong JH, Lee K-H, Kim HJ, Jung JY, Koh S-J, Lee KE, Kim H-J, Park KH, Lim S, Park YH, Kim TH, Kim S, Yang Y, Kim S, Sohn J. Hematology and Oncology, CHA Bundang Medical Center, Seongnam, Republic of Korea; Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Hematology-oncology, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea; Division of Medical Oncology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; Division of Hematology and Medical Oncology, Seoul National University Hospital, Seoul, Republic of Korea; Division of Oncology/Hematology, Soonchunhyang University Cheonan Hospital, Cheonan, Republic of Korea; Department of Internal Medicine, Dongtan Sacred Heart Hospital, College of Medicine, Hallym University, Hwaseong, Republic of Republic; Division of Hematology and Oncology, Ulsan University Hospital, Ulsan University College of Medicine, Ulsan, Republic of Korea; Division of Hematology and Oncology, Ewha Womans University Hospital, Seoul, Republic of Korea; Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea; Division of Medical Oncology/Hematology, Korea University College of Medicine, Seoul, Republic of Korea; Wonju Severance Christian Hospital, Wonju, Republic of Korea; Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Department of Pathology, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea; Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea; Department of Biomedical Systems Informatics, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea.
   
  Treatment - Types and Sites of Breast Cancer: Bone Metastases
P1-20-01 Immune microenvironment change of breast cancer and bone metastasis
Chao X, Zhang Y, Lu J, Sun P He J. Sun Yat-sen University Cancer Center, Guangzhou, China.
P1-20-02 A machine learning approach to identify risk factors associated with skeletal-related events following denosumab cessation among patients with bone metastases from breast cancer
Stopeck A, Higano C, Henry D, Bachmann B, Rehn M, Jacobson D, Cadieux B, Saad H. Stony Brook Cancer Center, Stony Brook University, New York, NY; University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA; University of Pennsylvania, Pennsylvania Hospital, Philadelphia, Philadelphia, PA; Amgen Inc., Thousand Oaks, CA.
   
  Treatment - Types and Sites of Breast Cancer: Brain Metastases
P1-21-01 Multicenter study for brain metastasis from breast cancer in Korea: The significance of molecular subtype (KROG 1612)
Kim JS, Kim K, Jung W, Shin KH, Im S-A, Kim H-J, Kim YB, Chang JS, Kim JH, Choi DH, Park YH, Kim DY, Kim TH, Choi BO, Lee S-W, Kim S, Kwon J, Kang KM, Chung W-K, Kim KS, Yoon WS, Kim JH, Cha J, Oh YK, Kim IA. Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea; Department of Radiation Oncology, Ewha Womans University College of Medicine, Seoul, Republic of Korea; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea; Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea; Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Proton Therapy Center, National Cancer Center, Goyang, Republic of Korea; Department of Radiation Oncology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; Department of Radiation Oncology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea; Department of Radiation Oncology, Chungnam National University College of Medicine, Daejeon, Republic of Korea; Department of Radiation Oncology, Gyeongsang National University School of Medicine and Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea; Department of Radiation Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Republic of Korea; Department of Radiation Oncology, Dongnam Institute of Radiological and Medical Sciences, Busan, Republic of Korea; Department of Radiation Oncology, Ansan Hospital, Korea University Medical College, Ansan, Republic of Korea; Department of Radiation Oncology, Keimyung University Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Republic of Korea; Department of Radiation Oncology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea; Department of Radiation Oncology, Chosun University Medical School, Gwangju, Republic of Korea.
P1-21-02 Scalp sparing whole-brain radiotherapy using IMRT technique. Do we need it?
Barsoum MS, Barsoum EM, Kamaleldin M, Mahmoud N, Abdelgeleel S, Ashour MG. Barsoum Oncology Center (BOC), Cairo, Egypt; Department of Clinical Oncology, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt; Biostatistics and Epidemiology Department, National Cancer Institute, Cairo University, Cairo, Egypt; Radiation Oncology and Nuclear Medicine Department, National Cancer Institute, Cairo University, Cairo, Egypt.
P1-21-03 Efficacy of tyrosine kinase inhibitors (TKI) in the treatment of patients with HER2-positive (HER2+) breast cancer with or without brain metastases: A systematic review and meta-analysis
Nader-Marta G, Martins-Branco D, Agostinetto E, Bruzzone M, Ceppi M, Lambertini M, Kotecki N, Awada A, de Azambuja E. Institut Jules Bordet, and l’Université Libre de Bruxelles (U.L.B), Belgium, Belgium; Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy, Genova, Italy; Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
P1-21-04 The real word study on clinical features and prognostic factors of Chinese breast cancer patients with brain metastasis
Wang T, Zhang H, Li F, Wu X, Zhou J, Zhang Sh, Bian L, Jiang Zf. The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
P1-21-05 GM-CSF is an autocrine driver of HER2+ breast leptomeningeal carcinomatosis
Bhan AK, Ansari KI, Chen C, Jandial R. City of Hope National Medical Center, Duarte, CA.
P1-21-06 Phase I study of T-DM1 and metronomic temozolomide in secondary prevention of HER2+ breast cancer brain metastases following local radiation therapy
Zimmer AS, Steinberg S, Gilbert M, Armstrong T, Burton E, Houston N, Smart DD, Biassou N, Butman J, Brastianos PK, Anders CK, Lipkowitz S, Steeg PS. National Cancer Institute, Bethesda, MD; Massachusetts General Hospital / Harvard University, Boston, MA; Duke Cancer Institute, Durham, NC.
P1-21-07 Implications for chronoradiobiology: Differential effect of radiation response for breast cancer patients with brain metastases depending on treatment time
Matlack L, Lombardo J, Nelson N, Smith A, Shi W, Simone N. Cooper Medical School of Rowan University, Camden, NJ; Thomas Jefferson University Hospital, Philadelphia, PA; Philadelphia College of Osteopathic Medicine, Philadelphia, PA.
P1-21-08 Brain metastases (BM) from breast cancer: Real-word data from the Austrian AGMT_MBC-registry
Gampenrieder SP, Rinnerthaler G, Tinchon C, Petzer A, Balic M, Heibl S, Zabernigg AF, Egle D, Sandholzer M, Roitner F, Andel J, Pichler P, Hager C, Knauer M, Hubalek M, Singer CF, Greil R. Department of Internal Medicine III, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University Salzburg, Salzburg, Austria; Internal Medicine - Department for Haemato-Oncology, LKH Hochsteiermark, Leoben, Austria; Internal Medicine I for Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Barmherzige Schwestern – Elisabethinen, Linz, Austria; Division of Oncology, Department for Internal Medicine, Medical University Graz, Graz, Austria; Department of Internal Medicine IV, Klinikum Wels-Grieskirchen GmbH, Wels, Austria; Department of Internal Medicine, County Hospital Kufstein, Kufstein, Austria; Department of Gynaecology, Medical University Innsbruck, Innsbruck, Austria; Department of Internal Medicine II, Academic Teaching Hospital Feldkirch, Feldkirch, Austria; Department of Internal Medicine II, Hospital Braunau, Braunau, Austria; Department of Internal Medicine II, Landeskrankenhaus Steyr, Steyr, Austria; University Hospital St. Pölten, Department for Internal Medicine 1, St. Pölten, Austria; Breast Center Dornbirn, Dornbirn, Austria; Breast Center Eastern Switzerland, St. Gallen, Switzerland; Department of Gynecology, Breast Health Center Schwaz, Schwaz, Austria; Department of Obstetrics and Gynecology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
   
  Treatment - Types and Sites of Breast Cancer: DCIS/LCIS
P1-22-01 Predictors of inaccurate pre-operative size assessment of screen detected DCIS and impact on recurrence rates
Kirwan CC, Hilton B, Clements K, Stobart H, Wallis M, Mylvaganam S, Provenzano E, Maxwell A, Sharma N, Shaaban A, Dodwell D, Dulson-Cox J, Sawyer E, Kearins O, Brace-McDonnell S, Pinder S, Thompson AM. University of Manchester, Manchester, United Kingdom; Public Health England, Birmingham, United Kingdom; Independent Cancer Patients Voice, London, United Kingdom; University of Cambridge, Cambridge, United Kingdom; The Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom; Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom; Queen Elizabeth Hospital Birmingham and University of Birmingham, Birmingham, United Kingdom; University of Oxford, Oxford, United Kingdom; King's College London and Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom; Baylor College of Medicine, Houston, TX.
P1-22-02 Subsequent risk of ipsilateral breast events in a multinational DCIS cohort of 48.619 patients: A meta-analysis within the PRECISION consortium
Schmitz RSJM, van den Belt-Dusebout SW, Cresta C, Liu Y-H, Schaapveld M, Clements K, Timbres J, Byng DT, Ryser MD, Ren Y, Lynch T, Hyslop T, Menegaz B, Collyar D, Hwang S, Thompson A, Sawyer E, Wesseling J, Lips EH, Schmidt MK, Grand Challenge PRECISION consortium. Netherlands Cancer Institute, Amsterdam, Netherlands; Public Health England, Birmingham, United Kingdom; King's College London, London, United Kingdom; Duke University, Durham, NC; Baylor College of Medicine, Houston, TX; Patient Advocates in Research, Danville, CA.
P1-22-03 Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ
Guerini Rocco E, Fumagalli C, Concardi A, Taormina SV, Guerrieri-Gonzaga A, Corso F, Gandini S, Bonanni B, Viale G, Barberis M, Fusco N, Matteo L. European Institute of Oncology (IEO), Milano, Italy; University of Milan, Milano, Italy.
P1-22-04 Decision aids and risk prediction models to support decision making about DCIS treatment: A systematic literature review
Schmitz RSJM, Wilthagen E, van Duijnhoven F, van Oirsouw M, Verschuur E, Lynch T, Punglia RS, Hwang S, Wesseling J, Schmidt MK, Bleiker E, Engelhardt EG, Grand Challenge PRECISION consortium. Netherlands Cancer Institute, Amsterdam, Netherlands; Borstkanker Vereniging Nederland, Utrecht, Netherlands; Duke University, Durham, NC; Dana-Farber Cancer Institute, Boston, MA.
P1-22-05 Identifying predictors of invasive recurrence based on molecular profiles of DCIS lesions
Bismeijer T, Ahmed AA, Sheinman M, Roman-Escorza M, Shah V, Marks JR, King LM, Megalios A, Visser LL, Hoogstraat M, Davies HR, Kumar T, Collyar D, Stobart H, Navin NN, Futreal A, Nik-Zainal S, Hwang S, Lips EH, Thompson A, Wessels LFA, Sawyer EJ, Wesseling J, Grand Challenge PRECISION Consortium. Oncode Institute and Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, Netherlands; School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy’s Cancer Centre, King’s College London, London, United Kingdom; Department of Surgery, Duke University School of Medicine, Durham, NC; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands; MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre and Academic Department of Medical Genetics, Cambridge Biomedical Research Campus, Cambridge, United Kingdom; Department of Genomic Medicine, MD Anderson Cancer Center, Houston, TX; Patient Advocates in Research, Danville, CA; Independent Cancer Patients’ Voice, London, United Kingdom; Department of Genetics, MD Anderson Cancer Center, Houston, TX; Department of Surgical Oncology, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX; Oncode Institute and Division of Molecular Carcinogenesis, The Netherlands Cancer Institute and Faculty of Electrical Engineering, Mathematics, and Computer Science, Delft University of Technology, Amsterdam, Netherlands; Division of Molecular Pathology and Division of Diagnostic Oncology, The Netherlands Cancer Institute and Department of Pathology, Leiden University Medical Center, Amsterdam, Netherlands.
P1-22-06 A longitudinal cohort study of outcomes in 311 women with unresected ductal carcinoma in situ detected through the English breast screening programme
Clements K, Maxwell A, Hilton B, Wallis M, Kirwan C, Stobart H, Provenzano E, Sharma N, Litherland J, Shaaban A, Dodwell D, Dulson-Cox J, Sawyer E, Mylvaganam S, Kearins O, Brace-McDonnell S, Pinder S, and Thompson A. Public Health England, Birmingham, United Kingdom; University of Manchester, Manchester, United Kingdom; Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom; Independent Cancer Patients' Voice, London, United Kingdom; Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom; NHS Greater Glasgow and Clyde, Glasgow, United Kingdom; Queen Elizabeth Hospital Birmingham and University of Birmingham, Birmingham, United Kingdom; University of Oxford, Oxford, United Kingdom; King's College London and Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom; Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom; Baylor College of Medicine, Houston, TX.
P1-22-07 Surgical outcomes of lobular carcinoma in situ diagnosed on core biopsy in Dutch women between 2011 and 2020
Westenend PJ, Kerkhoven C, Meurs CJC, Siesling S. Laboratory of Pathology, Dordrecht, Netherlands; CMAnalyzing, Zevenaar, Netherlands; Department of Research, Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands.
P1-22-08 Withdrawn
   
  Treatment - Types and Sites of Breast Cancer: Male Breast Cancer
P1-23-01 Male breast cancer- a 20 year multi-center experience
Zheng G, Wang H, Liu F-Y, Leone JP. St Elizabeth Medical Center, Brighton, MA; Dana Farber Cancer Institute, Boston, MA.
P1-23-02 Incidence, clinicopathological features and treatment patterns of male breast cancer (MBC) in a high-volume cancer center in the United Arab Emirates (UAE)
Al-Awadhi A, Yousif A, Balalaa N, Luiten E, Jelovac D. Tawam Hospital, Al Ain, United Arab Emirates; Johns Hopkins University, Baltimore, MD.
P1-23-03 Male breast cancer in a retrospective study from the Maria Sklodowska Curie National Research Institute of Oncology in Warsaw, Poland
Jagiello-Gruszfeld AI, Winter P, Wojcik R, Kunkiel M, Sienkiewicz R, Dubianski R, Majstrak-Hulewska A, Nowecki Z. Maria Sklodowska-Curie National Research Institute of Oncology, Warszawa, Poland.
   
  Treatment - Types and Sites of Breast Cancer: Inflammatory Breast Cancer
P1-24-01 Does modified radical mastectomy in de novo stage IV inflammatory breast cancer patients improve disease specific survival?
Chen JC, Li Y, Fisher JL, Tsung A, and Samilia Obeng-Gyasi S. The Ohio State University, Columbus, OH.
P1-24-02 Genetic variants and tumor microenvironment in inflammatory breast cancer: Clues for targeted therapies
Arisi MF, Gong Y, Nagarathinam R, Gerratana L, Pei J, Cai KQ, Winn J, Hasse Z, Obeid E, Noriega J, Sebastiano C, Ross E, Alpaugh RK, Cristofanilli M, Fernandez SV. Thomas Jefferson University, Philadelphia, PA; Fox Chase Cancer Center, Philadelphia, PA; Northwestern University, Chicago, IL.
P1-24-03 Clinicopathological characterization of inflammatory breast cancer in the Netherlands: First results of the prospective INFLAME registry
van Geel JJL, van der Schoor G, van Leeuwen-Stok E, Martens JWM, Wilting SM, Wesseling J, Sonke GS, Schröder CP. University Medical Center Groningen, Groningen, Netherlands; Dutch Breast Cancer Trialists' Group (BOOG), Amsterdam, Netherlands; University Medical Center Rotterdam, Rotterdam, Netherlands; Netherlands Cancer Institute, Amsterdam, Netherlands.
P1-24-04 Spatially resolved cell type heterogeneity uncovers the distinct biology of inflammatory breast cancer
Courtois E, Flynn W, Sivajothi S, Seignon M, Luo D, Lim B, Robson P. The Jackson Laboratory, Farmington, CT; Baylor College of Medicine, Houston, TX.
P1-24-05 Breast conserving surgery for non-metastatic inflammatory breast cancer: A National Cancer Database (NCDB) study
Angarita FA, Edge SB, Attwood K, Takabe K, Young J. Roswell Park Comprehensive Cancer Center, Buffalo, NY.
P1-24-06 Risk factor modeled microenvironment effects lymphatics activity and IBC invasiveness and progression
Balema W, Morton J, Larson R, Velasquez FC, Sevick-Muraca E, Woodward WA. University of Texas MD Anderson Cancer Center, Houston, TX; University of Texas Health Science Center at Houston, Houston, TX.
P1-24-07 Management trends and outcomes assessment for inflammatory breast cancer
Tran J, Valente S, Tu C, Kruse M. Cleveland Clinic Foundation, Cleveland, OH.